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ABSTRACT 
Emily Newman Gallichotte: The Human Antibody Response to DENV2 Infection and 
Vaccination 
(Under the direction of Aravinda de Silva and Ralph Baric) 
 
Dengue viruses (DENVs) are mosquito-borne flaviviruses that are estimated to infect 
390 million people each year. Dengue is a major global public health concern because people 
infected with the virus can develop dengue fever or severe dengue hemorrhagic fever and 
shock syndrome. Vaccines offer the best hope for controlling the current global DENV 
pandemic. The major goal of my thesis project was to define the properties of neutralizing and 
protective human antibodies stimulated by natural DENV infections and the leading live 
attenuated DENV vaccines.  
 
There are four antigenically distinct DENV serotypes, named DENV1 through DENV4. 
For my studies, I focused on DENV2 as a model to understand human protective immunity 
following infection or vaccination. Following natural DENV2 infections, individuals generate 
strongly neutralizing DENV2 serotype-specific antibodies, which provide protection against 
subsequent DENV2 infections. I characterized the properties and specific epitopes of multiple 
human DENV2 serotype-specific strongly neutralizing monoclonal antibodies, and discovered 
two major antigenic sites on domain III and domain I of the DENV2 envelope protein. 
Additionally, I found that the majority of DENV2 serotype-specific polyclonal antibodies present 
in immune sera also target quaternary epitopes as defined by these DENV2 monoclonal 
antibodies.  
iv 
 
I sought to determine if DENV vaccination is able to elicit the same types of DENV2 
antibodies implicated in protective immunity following natural infections. I observed that two 
different live DENV vaccines were able to elicit antibodies targeting epitopes similar to those 
targeted by antibodies following natural DENV2 infections, suggesting that these vaccines might 
be protective against DENV2 challenge.  
 
Investigators studying DENV pathogenesis and vaccines had previously focused on the 
functional properties (neutralization) of human antibodies, with little consideration of the actual 
epitopes and mechanisms of protective immunity. Recent results from vaccine trials indicate 
that the mere presence of antibodies capable of neutralizing DENV in cell culture assays was 
not sufficient for protection from WT DENVs. My studies provide an in-depth view of the 
molecular specificity of serotype-specific human antibodies that neutralize DENVs. As a result of 
my thesis work, it is now possible to go beyond neutralizing antibodies and define the fine 
specificity and other properties of serotype-specific antibodies induced by infection or 
vaccination. My studies shed light on the protective immune response to DENV infections, 
which can ultimately be harnessed to evaluate current DENV vaccines, and improve the design 
of the next-generation of DENV vaccines. 
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CHAPTER 1 – The Molecular Specificity of the Human Antibody 
Response to Dengue Virus Infections1 
 
1.1 Summary 
Dengue viruses (DENV) are mosquito-borne positive sense RNA viruses in the family 
Flaviviridae. The four serotypes of DENV (DENV1, DENV2, DENV3, DENV4) are widely 
distributed and it is estimated over a third of the world’s population is at risk of infection (1). 
While the majority of infections are asymptomatic, DENV infection can cause a spectrum of 
disease, from mild flu-like symptoms, to the more severe DENV hemorrhagic fever and shock 
syndrome (2). Over the past 20 years, there have been intense efforts to develop a tetravalent 
live-attenuated DENV vaccine (3). The process of vaccine development has been largely 
empirical, because effective live attenuated vaccines have been developed for other flaviviruses 
like yellow fever and Japanese encephalitis viruses. However, recent results from Phase III live 
attenuated DENV vaccine efficacy trials are mixed with evidence for efficacy in some 
populations but not others (4). In light of unexpected results from DENV vaccine trials, in this 
chapter we will review recent discoveries about the human antibody response to natural DENV 
infection and discuss the relevance of this work to understanding vaccine performance.  
 
1.2 DENV Structure 
The DENV genome encodes a single open reading frame that is translated into a 
polyprotein. Viral and host proteases cleave the polyprotein into three structural and seven non-
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2 
structural viral proteins. The structural envelope protein (E) contains three domains, domain I 
(EDI), domain II (EDII) and domain III (EDIII) (5). Two envelope monomers come together in a 
head-to-tail orientation, forming the E dimer (Figure 1.1). Three E dimers form the dimer raft, 
and 30 dimer rafts cover the surface of the DENV virion in icosahedral orientation with both 3-
fold and 5-fold axes of symmetry. Domain II contains the hydrophobic fusion peptide, which 
mediates fusion between the virus and host cell membrane. To prevent fusion with the host-
membrane during egress from infected cells, the pre-membrane (prM) protein covers the fusion 
loop. As the virus moves through the endosome, pH changes triggers the host protease furin to 
cleave the prM protein (6). As the virus is released from cells, cleaved prM dissociates from the 
virion. This process is inefficient however, leaving a heterogeneous population of fully mature 
(no prM present), fully immature (containing prM), and partially mature virions (7). While cell 
culture grown virus shows a spectrum of maturation states, it is now clear that the overall 
maturation state of virions can vary between strains and even between different preparations of 
the same strain (8). As we discuss later, maturation state can influence the ability of some 
antibodies to bind and neutralize DENV and other flaviviruses.  
 
1.3 Antibody Response to DENV Infection 
The basic kinetics of the DENV specific Ab response, the timing of IgM and IgG Ab 
development and the timing of neutralizing antibody (Nab) development have been well 
understood for many years (9-11). In brief, individuals with no prior immunity to DENVs mount a 
primary antibody response that includes a specific IgM response followed by a durable IgG 
response. The initial IgG response contains different types of antibodies, including serotype 
cross-reactive neutralizing antibodies, serotype cross-reactive non-neutralizing antibodies, and 
serotype-specific neutralizing antibodies (12). The serotype cross-reactive neutralizing 
antibodies may provide immediate protection to subsequent infection with any of the DENV 
serotypes, but these antibodies wane over the course of a year. DENV serotype-specific 
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neutralizing antibodies and some cross reactive poorly neutralizing antibodies are maintained 
for decades following infection and appear to protect against subsequent re-infection with the 
same serotype, but do not protect against the other serotypes (Figure 1.2). Conversely, cross-
reactive antibodies not only are non-protective, but can enhance subsequent infection via a 
mechanism known as antibody dependent enhancement (ADE) whereby non-neutralizing 
antibodies bind the virus and the antibody-virus complex is taken up by cells via FC-receptor 
mediated endocytosis (13). Although ADE is poorly understood, the response is important in 
natural infection and vaccine development but will not be discussed in this review. Readers are 
recommended to refer to these earlier reviews for additional information on ADE and DENV (13-
15).  
 
1.4 Methods to Study the Molecular Specificity of Human Antibodies to DENVs 
A variety of techniques have been used to map the viral epitopes targeted by polyclonal 
antibodies in human immune sera and monoclonal antibodies (MAbs) isolated from dengue 
patients (Figure 1.3). Traditionally, to study DENV-specific MAbs, peripheral blood B-cells from 
DENV immune donors are transformed and clones secreting DENV-reactive MAbs are fused 
with myeloma cell lines to generate human hybridomas producing the MAb of interest (16, 17). 
Recent advances in single-cell-sequencing has allowed individual IgG heavy and light chains 
from the same cell to be sequenced, cloned and recombinantly expressed (18, 19). The 
properties and specificity of these MAbs can then be determined using binding assays to 
recombinant DENV proteins (rE and rEDIII) and whole virions, and neutralization assays, as 
well as by solving high-resolution structures of the MAb bound to viral antigen. Once a putative 
MAb epitope has been identified, recombinant viruses with point mutations at the region of 
interest can be used to confirm and further refine the epitope. Importantly, these studies have 
revealed that most DENV neutralizing epitopes are created by presentation of discontinuous 
residues that are brought together in tertiary and quaternary structures. Additionally, our group 
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has shown that the discontinuous residues that comprise these complex epitopes can be 
transplanted to a different serotype to generate chimeric DENVs that encode neutralizing 
epitopes from multiple DENV serotypes, and which can be used to map and confirm the binding 
and neutralization of individuals MAbs (20, 21).  
 
Polyclonal sera contains a complex mixture of DENV-specific IgG antibodies, those that 
are neutralizing or non-neutralizing, and those that are specific to a serotype or cross-reactive to 
multiple serotypes (Figure 1.2). Depletion assays can be used to determine the percentage of 
neutralizing serotype-specific antibodies to neutralizing cross-reactive antibodies (Figure 1.3A). 
To remove cross-reactive Abs, primary infection sera can be incubated with beads coated with a 
heterologous serotype (e.g. a primary DENV2 sera can be incubated with 
DENV1/DENV3/DENV4-coated beads). Cross-reactive Abs will bind to the virus on the beads 
and be pelleted out, leaving only DENV2 serotype-specific Abs. Neutralization assays using 
depleted sera allow one to calculate the fraction of neutralization due to serotype specific Abs, 
relative to the total neutralization coming from both serotype-specific and cross-reactive Abs 
(22-24). These depletion techniques, in addition to use of epitope transplant chimeric rDENVs 
described above, has allowed us to study the amount of polyclonal antibodies targeting epitopes 
represented by individual MAbs (21, 23).  
 
1.5 Molecular Specificity of Neutralizing MAbs from Primary Cases 
The most striking feature of primary DENV infections is the rapid clearance of the virus 
and the maintenance of serotype-specific neutralizing Abs in the serum in most individuals for 
decades if not longer. Recent studies have only begun to define the molecular specificity of 
human B-cells and antibodies responsible for durable type-specific neutralization and protection. 
The envelope protein is the major antigenic protein; the majority of DENV-specific antibodies 
target E (5). Traditionally human monoclonal antibodies (MAbs) have been screened based on 
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their ability to bind recombinant envelope monomeric protein (rE). This has biased our study of 
MAbs to those that recognize simple epitopes; their epitopes are contained within a single E 
protein. Recent work by many groups has expanded this study to screen antibodies based on 
their ability to bind the entire DENV virion (25, 26). This work has identified antibodies from each 
serotype that recognize complex, quaternary epitopes, which are assembled from higher-order 
structures that span across monomers, dimers, rafts, or require specific angles or presentation 
of E, that is only present on the intact virus (Figure 1.4). Additionally, it has been found that 
while antibodies using simple epitopes can be neutralizing, it is the antibodies recognizing 
complex epitopes that are ultimately responsible for polyclonal neutralization (21, 27, 28). 
Antibodies recognizing quaternary epitopes are not unique to DENV; West Nile Virus (WNV) 
and Zika Virus (ZIKV) have also been shown to generate human MAbs recognizing similar 
complex epitopes (29-32).  
 
1.6 Differences in Neutralizing MAb Epitopes Across Serotypes 
While the E protein is around 80% conserved across all four DENV serotypes, it appears 
the different serotypes may use different immunodominant epitopes (Figure 1.4). Unlike anti-
DENV mouse MAbs that predominantly target EDIII (33, 34), many human MAbs use EDI, EDII, 
and the EDI/II hinge region in their epitopes. For example, DENV1 MAbs 1F4 and 14C10 use a 
quaternary EDI epitope that spans across dimers within the raft and can reach into EDIII of the 
neighboring dimer (35, 36). Interestingly, this epitope is highly similar to a human WNV MAb 
CR4354, suggesting WNV might use a similar immunodominant epitope (32). The DENV3 MAb 
5J7 targets an epitope centered around the EDI/II hinge region that is dependent on a specific 
hinge angle, only present on intact virion (37). Recent work has identified human DENV4 MAbs 
that target a similar epitope (23). Interestingly, DENV2 MAbs appear to use an epitope distinct 
to the EDI/EDII region, instead centering around EDIII (21, 38). Our understanding of 
immunodominant epitopes for each serotype is informed by only a handful of monoclonal 
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antibodies from a few immune individuals. To fully define the boundaries of the polyclonal 
neutralizing epitopes against each serotype, additional antibodies from more individuals will 
need to be studied.  
 
1.7 Cryptic Epitopes 
The majority of human epitopes studied are present on the surface of the intact virion. 
Some studies have identified mouse MAbs that target cryptic epitopes not readily accessible on 
the surface of the virus. However, at elevated temperature these cryptic epitopes are transiently 
displayed, allowing antibody binding and neutralization (39). Recent studies suggest that there 
are antibodies present in human immune sera that also target these cryptic epitopes, potentially 
allowing the virus to be neutralized when it is under specific conditions exposing these epitopes 
(39). However, we need to identify human MAbs that target these cryptic epitopes and 
determine their role and importance in neutralization and protective immunity.  
 
1.8 Other Flaviviruses – Zika Virus MAbs 
With the emergence of Zika virus (ZIKV), approaches developed for DENVs have been 
extended to isolate and map the human antibody response to ZIKV (29-31). Multiple groups 
have generated human ZIKV MAbs and characterized their epitopes on E. Individual MAbs have 
been identified with epitopes that span the whole E protein, but, similarly to DENV, the strongest 
neutralizing MAbs target quaternary epitopes only present on the intact ZIKV virion. These 
quaternary ZIKV epitopes are similar to previously identified quaternary DENV epitopes that are 
centered around the EDI/II hinge region, span across E monomers within the dimer, or span 
across dimers (29-31).  
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1.9 Mapping the Molecular Specificity of the Polyclonal Serum Neutralizing Antibody 
Response 
While MAbs are isolated or generated from memory B-cells, circulating polyclonal 
antibodies come from plasma cells (40). The memory B-cell derived human MAbs can be used 
as tools to interrogate the properties and specificity of the more complex polyclonal serum 
antibody response (Figure 1.5). Work by multiple groups have shown that individual MAbs can 
be representative of the anti-DENV B-cell repertoire, polyclonal Abs from the same individual, 
and polyclonal Abs across other naturally infected and vaccinated individuals, confirming the 
importance of studying individual monoclonals (21, 23, 41). Importantly, depletion assays have 
revealed that after primary DENV infections, the majority of polyclonal neutralization comes from 
serotype-specific antibodies, not cross-reactive ones (22-24). Additionally, we have found that 
epitopes defined by individual MAbs that are complex and quaternary, are representative of the 
polyclonal epitopes targeted by neutralizing serotype-specific antibodies (27, 28). With the rapid 
emergence of ZIKV, similar techniques as described above were applied to dissecting the 
antibody response to ZIKV infection. Multiple groups have found that strongly neutralizing ZIKV 
MAbs target complex quaternary epitopes (29-31). Additional work using depletion assays, has 
identified that primary ZIKV infections can results in ZIKV specific Abs, despite populations of 
Abs that cross-neutralize DENV (42). 
 
1.10 Molecular Specificity of Neutralizing Antibodies Following Secondary DENV 
Infection 
Individuals experiencing secondary DENV infections with a new serotype develop a 
neutralizing and protective antibody response that is fundamentally different from a primary 
infection-induced response. People with known sequential infections with two different DENV 
serotypes have type-specific antibodies to serotypes of infection and a new population of 
durable serotype-cross neutralizing antibodies that are also effective against serotypes not 
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encountered by the person (43). Human cohort studies in dengue-endemic countries have also 
established that tertiary infections are nearly always mild or inapparent, implicating a protective 
role for these broadly cross-neutralizing antibodies that develop after a second DENV infection 
(44). Figure 1.6 presents a model to explain the evolving antibody response following sequential 
DENV infections with different serotypes. The model is based on the premise that low affinity 
DENV cross reactive memory B-cells derived from primary infections undergo antibody somatic 
hyper mutation and each subsequent DENV exposure selects and expands rare affinity matured 
clones with greater neutralization breadth and potency (24). The model is supported by recent 
studies demonstrating that serotype cross-reactive antibodies derived from secondary infections 
had stronger neutralization potencies and higher binding avidities than those derived from 
patients with primary infections (45-49). 
 
While we know a lot about epitopes targeted by DENV serotype-specific neutralizing and 
protective antibodies, less is known about the targets of durable serotype-cross neutralizing 
antibodies. Several cross-neutralizing human MAbs that bind to an epitope near the bc-loop on 
domain II the E protein monomer have been recently described (Figure 1.7) (45, 50). Another 
class of serotype cross-reactive and strongly cross-neutralizing MAbs, which bind to quaternary 
epitopes on the E homodimer, was recently isolated from acute-phase plasmablasts in the 
peripheral blood of secondary DENV cases (25, 51). These MAbs, which have been designated 
E dimer epitope (EDE) antibodies, bind to epitopes that span domains I or III of one monomer 
and domain II of the adjacent monomer (Figure 1.7). It is unclear if the strongly cross-
neutralizing MAbs isolated from acute-phase plasmablasts are maintained as MBCs and LLPCs 
and responsible for the durable cross-neutralizing antibodies observed in people after recovery 
from secondary infections. Additionally, there are still unknowns regarding if the order of 
infecting serotypes is important for the epitopes of strongly cross-neutralizing Mabs. The 
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molecular mechanisms leading to the evolution of cross-neutralizing antibodies from the 
memory B-cell pool from a primary infection are also unclear. 
 
1.11 NS1 and prM MAbs 
While E is the major antigenic protein of DENV, antibodies are also generated targeting 
the viral proteins NS1 and prM. The host sees prM protein in several configurations. As mature 
viruses are released from infected cells, prM protein dissociates from the virus and is released 
as an antigen. Additionally, immature viruses have prM present on their surface, allowing the 
immune system to recognize them as part of the virus. prM antibodies are predominantly non-
neutralizing enhancing antibodies; they allow non-infectious immature viruses to be taken up 
into cells via FC-receptor-mediated endocytosis (52).  
 
DENV NS1 protein has many roles depending on its interactions and location (53, 54). 
NS1 can exist as a monomer, dimer or hexamer, and is important in viral RNA replication, viral 
assembly and release, and immune evasion. NS1 is secreted from infected cells primarily as a 
hexamer, which can bind to endothelial cells, triggering hyperpermeability, leading to vascular 
leakage seen in severe DENV disease (55). Clinically, levels of circulating NS1 are correlated 
with disease severity (56, 57). People infected with DENV make antibodies directed against 
NS1, but is unclear if these are an important part of the protective immune response, or are 
merely a consequence of high levels of circulating viral antigen (54).  
 
1.12 Mechanisms of Neutralization 
MAbs can neutralize viruses through a variety of mechanisms. MAbs have been shown 
to neutralize DENV by blocking attachment to host cell receptors, binding directly to the fusion-
loop, binding across E proteins preventing conformational changes required for fusion, as well 
as via opsonization. Anti-DENV MAbs have been shown to neutralize using many of these 
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mechanisms (37, 38, 51, 58). DENV maturation state (amount of prM present) and virus 
breathing are important factors for virus neutralization. A fully immature virus (i.e. 180 copies of 
prM present) is non-infectious, and therefore cannot be neutralized, but a partially mature virus, 
can still be infectious (59). Alternatively, under certain temperature conditions, some DENV 
strains can undergo reversible conformational changes where the E proteins expand and 
contract analogous to “breathing”. These expansion and contraction changes can reveal or hide 
epitopes, limiting neutralization by antibodies recognizing these epitopes to specific conditions 
(39, 60-62). While DENV maturation and “breathing” have been studied in cell culture systems, 
the importance of these phenomenon in natural infection, and therefore the potential impact on 
antibody neutralization, is not well understood.  
 
1.13 Implications for Evaluating Antibodies to DENV Live Attenuated Vaccines (LAVs) 
Recently we have learned important lessons from DENV tetravalent vaccine clinical 
trials. The leading tetravalent vaccine had variable efficacy depending on DENV serotype and 
vaccinated population (4). The vaccine had higher efficacy in DENV-primed individuals 
compared to DENV naïve individuals who received the vaccine, establishing the impact of 
immunological memory on vaccine performance (63). The population with the greatest need for 
a DENV vaccine is young children, the majority of whom will be DENV-naïve at vaccination. As 
discussed above, in people exposed to primary natural DENV infections, the neutralizing and 
protective antibody response is dominated by type-specific antibodies to quaternary epitopes. 
Therefore, in this population the success of tetravalent vaccination is likely to require balanced 
replication of the four vaccine viruses leading to type-specific antibodies that target quaternary 
epitopes in each serotype. 
 
As discussed above, secondary DENV infections result in activation of memory B-cells 
and development and expansion of cross-reactive antibodies that broadly neutralize multiple 
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DENV serotypes, driven by the sequential infection and robust replication of two different 
serotypes of DENV (24). A similar mechanism is likely to be responsible for the superior 
performance of tetravalent LAVs in DENV-primed individuals. In a subject with pre-existing 
DENV-specific MBCs, even unbalanced replication of one or two vaccine components is likely to 
activate MBCs and expand somatically mutated higher-affinity cross-reactive clones with 
capacity to broadly neutralize multiple serotypes.  
 
Immune correlates of protection and vaccine efficacy are urgently needed. For the 
leading DENV vaccine, the mere presence of in vitro neutralizing antibodies was not sufficient 
for protection because many individuals experienced breakthrough infections despite having 
neutralizing antibodies to the breakthrough serotype (63). The lessons we have learned from 
natural infections studies about the molecular specificity of human antibodies to DENV infection 
may also lead to more robust correlates of vaccine efficacy than mere levels of total neutralizing 
antibodies (3). Certainly, the reagents and tools are now available to interrogate vaccine 
responses in a manner similar to that we have described here for natural DENV infections. 
 
1.14 Objectives of this Dissertation 
Despite DENV being endemic in over 100 countries, with a third of the world’s population 
at risk for infection, and almost 400 million infections yearly (1), there are still many aspects of 
the DENV infection that are poorly understand. Importantly, in most individuals, natural 
exposure to infection results in a robust adaptive immune responses, which provide subsequent 
protection against reinfection with the same serotype. Within this immune response, we known 
that strongly neutralizing antibodies play a critical role in subsequent protection from reinfection, 
but we still do not have a complete understanding of the properties of protective antibodies and 
the mechanisms of antibody mediated protection. 
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Early research on immunity to DENVs relied heavily on monoclonal antibodies (MAbs) 
generated in mice. Extensive studies with mouse MAbs identified a primary epitope in EDIII of 
the envelope glycoprotein recognized by strongly neutralizing antibodies (64). Subsequent 
studies revealed that, while this epitope is immuno-dominant in mice, only a small portion of the 
human serological response targets this EDIII epitope (28, 64, 65). This research revealed that 
the human antibody response to DENV infection is distinct from that in a mouse, and therefore 
to fully characterize it, we must isolate and charactize the activies of human DENV antibodies 
(64). Unlike mouse EDIII epitopes, it was found that human strongly neutralizing MAbs for 
DENV1, DENV3 and DENV4 target an epitope centered near the EDI/II hinge region (23, 27). 
Importantly, these are not simple epitopes present on recombinant proteins, but quaternary; 
they are only present on the fully assembled infectious virion (23, 27). Recent advances have 
shown that polyclonal serum neutralizing antibodies are also directed to quaternary structure 
epitopes defined using MAbs (23, 27).  
 
Cell culture based assays can determine levels of neutralizing antibodies present in 
serum, and it was hoped that this could be developed as a correlate of protection, especially for 
developing and evaluating DENV vaccines (66, 67). The recent clinical trials from Dengvaxia, 
Sanofi Pasteur’s tetravalent DENV vaccine, have revealed that some individuals with high levels 
of neutralizing antibodies experience DENV breakthrough infections (68, 69). Of note, vaccine 
efficacy was worst against DENV2, highlighting the weakness of the DENV2 component in 
eliciting a robust, protective antibody response (68). These results highlighted the discrepancy 
between the mere presence of neutralizing antibodies and protection against natural infection as 
individuals with neutralizing antibodies, experienced natural breakthrough infections. Addition 
work distinguishing between different populations of antibodies potentially revealed a 
mechanism to explain the large differences in vaccine efficacy across serotypes. 
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DENV polyclonal immune sera are comprised of multiple populations of antibodies, 
including type-specific antibodies specific to the infecting serotype, and weakly neutralizing 
cross-reactive antibodies (12). It is thought that cell-culture based assays can over-represent 
the neutralization potency by cross-reactive antibodies. Using depletion techniques we can 
study the contribution of each of these populations of antibodies on total neutralization (27, 70). 
Recent work identified that Dengvaxia vaccine sera contains large populations of DENV4 
serotype-specific neutralizing antibodies, however DENV1-3 neutralization is driven primarily by 
cross-reactive antibodies (22). Analysis of vaccine sera from individuals who experienced 
breakthrough infections, versus those who did not, we can potentially determine an improved 
antibody and epitope based correlate of protection, by specifically measuring the quality of 
antibodies elicited by vaccination.  
 
Identifying the dominant epitopes targeted by human DENV2 serotype-specific 
monoclonal and polyclonal antibodies is critical for refining our understanding of response to 
infection and vaccination. Detailed characterization of these DENV2 antibodies and the epitopes 
they target, will improve our understanding of the complex adaptive immune response to DENV 
infection, and can be harnessed to improve design and evaluation of DENV vaccines.  
 
We hypothesize that 1) DENV2 serotype-specific neutralizing antibodies target multiple 
quaternary epitopes on the envelope glycoprotein, 2) that generating a robust DENV2-specific 
antibody response directed to these epitopes is critical for vaccine-elicited protection, and that 
3) DENV1-specific neutralizing epitopes are distinct from those of DENV2, but can be mapped 
and studied using similar techniques. 
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AIM 1: Map the epitopes of human DENV2 serotype-specific monoclonal and polyclonal 
antibodies using recombinant DENVs, chimeric epitope transplant viruses, monoclonal 
blockade/competition assays, binding and neutralization assays.  
 
AIM 2: Evaluate the DENV2 serotype-specific neutralizing antibody response following 
tetravalent DENV vaccination, by determining the quality of DENV2 neutralizing antibodies, the 
epitopes they target, and whether these responses differ in individuals who experienced DENV2 
breakthrough infections, versus those who did not. 
 
AIM 3: Map the epitopes of DENV1 serotype-specific monoclonal antibodies by characterizing a 
DENV1 infectious clone, and by using an epitope transplant viruses in binding and neutralization 
assays. 
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Figure 1.1. Structure of DENV. A) Linear schematic of DENV envelope (E) protein. DENV E 
protein dimer composed of two monomers with domains I, II and III colored in red, yellow and 
blue respectively. B) DENV virion structure composed of 30 rafts, each containing three E 
dimers. 
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Figure 1.2. Antibody response following DENV infection. Following primary DENV2 
infection, there is an IgG response composed of neutralizing DENV2 serotype-specific 
antibodies, a transient population of cross-reactive neutralizing antibodies, and long-lived cross-
reactive non-neutralizing antibodies. After a secondary infection, in this case with DENV3, the 
cross-reactive non-neutralizing antibodies become strongly neutralizing. It is also possible to 
generate a new population of neutralizing serotype-specific antibodies to the second infecting 
serotype. 
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Figure 1.3. Methods to dissect DENV antibody response. A) Human DENV antibodies can 
be studied using a variety of approaches. PBMCs from a DENV immune donor can be EBV-
transformed to generate MAb producing hybridomas, or antibody DNA sequences can be 
single-cell sequenced, cloned and recombinant expressed to generate MAbs. DENV polyclonal 
immune sera can be depleted of different populations of antibodies using beads coated with 
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DENV antigens to determine the relative importance and neutralization capacity of these 
different populations. For example, a DENV2 immune sera containing polyclonal Abs (PAbs) 
can be depleted of all DENV cross-reactive antibodies by incubating with beads adsorbed with 
DENV1, DENV3, and DENV4 antigen, leaving only DENV2 serotype-specific antibodies 
remaining (heterotypic depletion). Conversely, all DENV antibodies can be depleted using 
DENV2 antigen (homotypic antigen). B) To map the binding and neutralizing epitopes of these 
MAbs and PAbs, they can be evaluated for their ability to bind recombinant E domain III (rEDIII), 
recombinant E (rE), whole DENV, and chimeric viruses containing transplanted epitopes of 
multiple DENV serotypes (e.g. rDENV1/3 contains epitopes from both DENV1 and DENV3). 
These MAbs and PAbs can also be evaluated for their ability to neutralize these DENV and 
chimeric rDENV. 
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Figure 1.4. Epitopes recognized by DENV serotype-specific human neutralizing MAbs. 
Serotype-specific neutralizing human MAbs isolated from primary infections recognize different 
quaternary structure epitopes displayed on the viral envelope. 
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Figure 1.5. From MAbs to polyclonal serum Abs. Complex host generic diversity, exposure 
history, and immune differences can make it challenging to study DENV polyclonal antibody 
responses across a population. Studying DENV antibody immunity in a single individual can 
simplify these analyses, however there is still the polyclonal nature of the adaptive immune 
response. Conversely, we can characterize the properties of individual MAbs from DENV 
immune donors. Information learned from MAbs can then be used to inform study of the B-cell 
repertoire from that, and other donors. Additionally, it can be determined whether the individual 
MAbs represent the polyclonal antibodies in that donor, and in a larger DENV immune 
population. 
 
DENV immune/vaccinated 
population Polyclonal  
DENV immunity 
PBMCs 
DENV MAbs 
  
 
21 
 
 
Figure 1.6. Model of B-cell maturation following sequential DENV infections. With each 
successive DENV infection, the ratio of serotype-specific (TS) and cross-reactive (CR) 
antibodies that contribute to DENV neutralization changes. During a primary infection (DENV2 
in this example), dengue-specific naïve B-cells are activated and these cells give rise to both 
memory B-cells (MBCs) and antibody secreting long lived plasma cells (LLPCs). This primary 
response is dominated MBC and LLPCs clones producing low affinity, weakly neutralizing 
serotype CR antibodies. The primary response also contains rare MBC and LLPCs producing 
TS antibodies that strongly neutralize DENV2. Following a secondary infection with a new 
serotype (DENV3 in this example), the overall DENV-specific B-cell response will be dominated 
by the activation and expansion of DENV2 and 3 cross-reactive MBCs induced by the primary 
infection. MBCs producing CR antibodies that bind to the second infecting serotype with high 
affinity will be preferentially activated. These activated cells will reenter germinal centers and 
undergo further rounds of somatic hyper mutation. CR B-cells with high affinity for the second 
serotype will be selectively expanded to give rise to cross-reactive MBC and LLPCs that 
strongly cross-neutralize multiple serotypes. In the figure this increase in affinity and 
neutralization is depicted by an increase in the color gradient (light pink to bright pink) of CR B-
cells. Following a tertiary infection (DENV4 in this example), this process is repeated again and 
results in a population of CR MBCs and LLPCs that dominate the neutralizing antibody 
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response. While the B-cell clones producing TS strongly neutralizing antibodies are also likely to 
be maintained through each successive round of infection, the TS response will account for only 
a small fraction of the total neutralizing response. 
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Figure 1.7. EDE and other cross-reactive epitopes. Envelope dimer epitope 1 (EDE1) targets 
EDIII of one monomer and spans over the fusion loop region of EDII of the neighboring 
monomer. EDE2 uses a similar epitope, but is shifted to also expand into EDI of the first 
monomer. Another class of cross-reactive antibodies targets the highly conserved bc-loop 
region of EDII.  
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CHAPTER 2 – A new quaternary structure epitope on dengue virus serotype 2  
is the target of durable type-specific neutralizing antibodies2 
 
2.1 Summary 
Dengue virus serotype 2 (DENV2) is widespread and responsible for severe epidemics. 
While primary DENV2 infections stimulate serotype-specific protective responses, a leading 
vaccine failed to induce a similar protective response. Using human monoclonal antibodies 
(hMAbs) isolated from dengue cases and structure-guided design of a chimeric DENV, here we 
describe the major site on the DENV2 envelope (E) protein targeted by neutralizing antibodies. 
DENV2-specific neutralizing hMAb 2D22 binds to a quaternary structure epitope. We 
engineered and recovered a recombinant DENV4 that displayed the 2D22 epitope. DENV2 
neutralizing antibodies in people exposed to infection or a live vaccine tracked with the 2D22 
epitope on the DENV4/2 chimera. The chimera remained sensitive to DENV4 antibodies, 
indicating that the major neutralizing epitopes on DENV2 and -4 are at different sites. The ability 
to transplant a complex epitope between DENV serotypes demonstrates a hitherto 
underappreciated structural flexibility in flaviviruses, which could be harnessed to develop new 
vaccines and diagnostics. 
 
2.2 Importance 
Dengue virus causes fever and dengue hemorrhagic fever. Dengue serotype 2 (DENV2) 
is widespread and frequently responsible for severe epidemics. Natural DENV2 infections 
stimulate serotype-specific neutralizing antibodies, but a leading DENV vaccine did not induce a 
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similar protective response. While groups have identified epitopes of single monoclonal 
antibodies (MAbs), the molecular basis of DENV2 neutralization by polyclonal human immune 
sera is unknown. Using a recombinant DENV displaying serotype 2 epitopes, here we map the 
main target of DENV2 polyclonal neutralizing antibodies induced by natural infection and a live 
DENV2 vaccine candidate. Proper display of the epitope required the assembly of viral 
envelope proteins into higher-order structures present on intact virions. Despite the complexity 
of the epitope, it was possible to transplant the epitope between DENV serotypes. Our findings 
have immediate implications for evaluating dengue vaccines in the pipeline as well as designing 
next-generation vaccines. 
 
2.3 Introduction 
Dengue virus (DENV) is the most significant arboviral infection of humans, with an 
estimated 390 million infections and 96 million symptomatic cases annually (1). The DENV 
complex consists of four distinct serotypes (DENV1-4). Infection with one serotype induces 
long-term protective immunity to the homologous serotype only. In fact, immunity to one 
serotype is associated with an increased risk of severe disease upon subsequent infection with 
a different serotype, a confounding factor for vaccine design. Many dengue vaccines in clinical 
trials are tetravalent live-attenuated virus formulations that are designed to simultaneously 
induce protective immunity to all 4 serotypes (71-73). However, in phase 3 efficacy trials in Asia 
and Latin America, the leading vaccine was 50-78% efficacious against serotypes 1, 3 and 4 but 
only 35-42% efficacious against serotype 2 (74, 75). Here we describe the main site on DENV2 
recognized by type-specific and durable neutralizing antibodies in people exposed to natural 
infections, after administration of a candidate vaccine in humans and in macaques infected with 
wild-type dengue virus strains. 
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The DENV envelope glycoprotein (E) is the main target of protective antibodies (5). The 
E protein is composed of three domains: I, II and III (designated EDI, EDII and EDIII). Each 
DENV particle has 180 monomers of E that are organized into 90 dimers that cover the entire 
surface of the virus (76). The arrays of E proteins are arranged with icosahedral symmetry, with 
each asymmetric unit containing three E proteins. Some human monoclonal antibodies (hMAbs) 
that neutralize DENVs bind to quaternary structure epitopes that require assembly of E protein 
into homodimers or higer order structures (27, 36, 38, 51, 77). Followng infection or vaccination, 
it is a DENV-specific serum polyclonal antibody response that is responsible for protection. The 
principle targets of the human polyclonal antibody responses that neutralize DENVs have 
remained elusive.  
 
We recently described hMAb 2D22, which is a DENV2-specific strongly neutralizing 
antibody isolated from a person exposed to a primary DENV2 infection (27). A point mutation at 
amino acid position 323 in EDIII (residue highlighted in magenta in Figure 2.1A and B) led to 
complete escape from 2D22 neutralization, indicating that the epitope includes EDIII residues 
(27). Recently Fibriansah et al solved the structure of 2D22 bound to DENV2 and demonstrates 
that the antibody bound to a quaternary epitope that was formed by EDIII and EDII on two 
different monomers within a single dimer (38). While the structure of hMAb 2D22 was a major 
advance, it is not known if the structurally intriguing epitope defined by 2D22 is the main target 
of neutralizing and protective antibodies in people exposed to DENV2 infections or a vaccine.  
 
2.3 Results 
Design of recombinant DENV4/2 chimeric virus 
To further understand the role of EDIII in the epitope of 2D22 and DENV2 neutralizing 
antibodies in general, we designed and recovered a recombinant chimeric virus in which the 
entire DENV2 EDIII region was inserted into the backbone sequence of a DENV4 molecular 
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clone to create a recombinant virus, designated rDENV4/2 (Figure 2.2). The recombinant virus, 
which had 40 amino acid changes in EDIII compared to the parental wild-type (wt) DENV4 strain 
(Figure 2.1A and Table 2.1), grew to similar levels as the wt viruses in C6/36 insect cells and in 
a human monocytic cell line (U937) expressing dendritic cell-specific intercellular adhesion 
molecule-3-grabbing non-integrin (DC-SIGN), a know dengue receptor, but was partially growth 
impaired in Vero cells (Figure 2.1C). DENVs are assembled inside cells as immature virions 
containing premembrane proteins (prM), which are cleaved in the Golgi resulting in the 
formation of mature virions. Proteolytic cleavage of prM is inefficient and the population of 
virions released from infected cells is an admixture displaying different stages of maturation. As 
the maturation state of DENVs may influence the display of some epitopes and sensitivity to 
antibody neutralization (59, 62, 78), immunoblots were performed to compare the maturation 
state of the rDENV4/2 chimera and the wt parental strains. From C6/36 cells, DENV2 particles 
had high levels of prM and DENV4 particles had low levels of prM relative to E protein, 
indicating that DENV4 virions were more mature (Figure 2.1D). The rDENV4/2 chimera had a 
maturation state similar to DENV4 indicating that insertion of EDIII from serotype 2 minimally 
altered the maturation state of the backbone serotype 4 virus (Figure 2.1D). 
 
Monoclonal antibody binding and neutralization of rDENV4/2 
To further evaluate the impact of EDIII exchange on overall E protein topology and virion 
structure, we probed the rDENV4/2 chimera with a panel of epitope-mapped human and mouse 
monoclonal antibodies (Table 2.2). DENV cross-reactive MAbs 1C19, 1N5 and 1M7 (50) bound 
to the chimera, indicating the preservation of cross-reactive epitopes (Figure 2.3A). DVC3.7 and 
DV4-E88 engage serotype-specific epitopes on EDIII of DENV2 and 4 respectively (Figure 2.3B, 
C and Table 2) (26, 79). Consonant with recombinant virus design, DVC3.7 bound and 
neutralized the chimera, whereas DV4-E88 failed to bind or neutralize the chimera (Figure 2.3F 
and G). Binding to and neutralization by 5H2, a non-human primate DENV4 serotype-specific 
  
 
28 
MAb with an EDI epitope, is not disrupted in rDENV4/2, showing we have not affected epitopes 
present on other domains (Figure 3.2D, H and Table 2.2) (80). Overall, these results 
demonstrate that the rDENV4/2 chimera displays epitopes in a manner consistent with display 
on a properly folded and functional chimeric E protein. Transplantation of DENV2 EDIII into 
DENV4 also restored binding and neutralization by MAb 2D22, even though this antibody did 
not bind to DENV2 recombinant EDIII alone (Figure 2.3E, I and Table 2.2). We predict that the 
full 2D22 epitope required for antibody binding and neutralization includes EDIII as well as some 
conserved residues on adjacent domains, but that the residues on EDIII alone determine 
DENV2 specificity. Indeed the cryo-electron microscopy structure of 2D22 bound to DENV2 
demonstrates that the epitope consists of residues on EDIII and EDII of different monomers 
within a single dimer (38).  
 
Polyclonal sera neutralization of rDENV4/2 
Natural primary DENV2 infections cause long-lived serotype-specific neutralizing 
antibody responses that can be detected for decades after exposure. To determine if “2D22-
like” epitopes created by DENV2 EDIII transplantation into DENV4 were the main targets of 
these antibodies, neutralization assays were performed with well characterized human and 
rhesus macaque dengue immune sera (Table 2.3) and the rDENV4/2 and parental viruses. As 
expected, primary DENV2 immune sera strongly neutralized DENV2, but not DENV4 (Figure 
2.4A). Remarkably, in the majority of cases, these sera also efficiently neutralized the rDENV4/2 
virus at levels similar to those measured with DENV2, indicating that EDIII replacement was 
sufficient to recreate the major DENV2 neutralizing epitopes recognized by these sera. The 
rDENV4/2 virus remained fully sensitive to neutralization of DENV4 immune sera (Figure 2.4B). 
These data suggest that DENV2 and DENV4 type-specific neutralizing antibodies target 
different epitopes on the E protein, which are both preserved on the rDENV4/2 chimera. To 
determine if neutralization of rDENV4/2 is specific to DENV2 and DENV4 immune sera, and not 
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reflecting a global increase in sensitivity to neutralization by any dengue immune serum, a panel 
of primary DENV1 and DENV3 immune sera were tested against the same three viruses. The 
rDENV4/2 virus did not display increased sensitivity to neutralization by DENV1 or 3 immune 
sera (p>0.05; p>0.05), demonstrating that the chimeric virus was not globally sensitive to 
antibody neutralization (Figure 2.4C and D). 
 
DENV2 type-specific antibodies require complex epitope 
To determine if the DENV2 neutralizing epitope recognized by antibodies in immune 
sera was entirely contained within the transplanted EDIII or included residues on EDIII and 
adjacent domains, the human immune sera were depleted of antibodies binding intact DENV2 
virions or recombinant DENV2 EDIII (Figure 2.5) and then tested for ability to neutralize the 
rDENV4/2 virus (Figure 2.6). We have previously demonstrated that the recombinant DENV2 
EDIII protein is properly folded and contains well-defined epitopes such as the lateral ridge and 
A-strand epitopes recognized by some mouse and human neutralizing antibodies (28, 81). 
When six primary DENV2 human immune sera were depleted using DENV2 virions, between 
one half to three quarters of the neutralizing potency was lost depending on the serum sample 
(Table 2.4) (68% ± 21%). When the same sera were depleted using DENV2 rEDIII alone, five 
sera displayed minor loss in neutralization (22% ± 3%) and one sample (DT110) lost 58% of 
neutralization, a significantly smaller loss of neutralization than compared to DENV2 depletions 
(Table 2.4) (p<0.05). These results indicate that most DENV2 epitopes targeted by polyclonal 
type-specific human neutralizing antibodies require assembly of more higher order structures 
than simple domains or monomers of E protein. We conclude that “2D22-like” EDIII-containing 
quaternary epitopes are a major target of serotype 2-specific long-lived polyclonal neutralizing 
antibodies that develop after DENV2 infections. 
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To determine if dengue vaccines can induce “2D22-like” quaternary epitope targeted 
neutralizing antibodies, we tested sera from 5 subjects who had developed DENV2 neutralizing 
antibodies after receiving a monovalent live attenuated DENV2 vaccine developed by the NIH 
(82). The vaccine sera neutralized DENV2 and the rDENV4/2 chimera but not DENV4 
demonstrating that the vaccine induced neutralizing antibodies that tracked with the 
transplanted EDIII (Figure 2.4) (p<0.01). To determine if the vaccine induced antibodies also 
recognized a quaternary epitope that extended beyond EDIII, three vaccine sera were depleted 
of antibodies binding intact DENV2 virions or recombinant DENV2 EDIII and then tested for 
ability to neutralize the chimeric virus. In all three samples depletion with whole virus led to a 
nearly complete loss of neutralizing antibodies (Table 2.4). Removal of EDIII specific antibodies 
resulted in a loss of neutralizing antibodies in one vaccine sample, while the other two samples 
retained the majority of neutralizing antibodies after EDIII depletion (Table 2.4). Thus, the 
vaccine induced neutralizing antibodies that bind to epitopes contained within EDIII or more 
complex epitopes that extend beyond EDIII.   
 
2.5 Discussion 
We have described an approach using whole domain replacement to identify principal 
antigenic sites targeted by polyclonal antibodies following natural DENV infection or 
experimental live attenuated DENV vaccination. With the DENV4/2 chimera, we observed a 
clear gain of DENV2 neutralization and no loss of sensitivity to neutralization by DENV4 sera, 
suggesting that the principal DENV4 neutralizing epitopes are distinct from DENV2 epitopes. 
Importantly, these data demonstrate that a single recombinant DENV can be designed that 
encodes major neutralizing epitopes from two virus serotypes.  
 
Several recent studies point to the importance of quaternary epitopes as targets of 
human DENV neutralizing antibodies (27, 36, 38, 51, 77). DENV1 and 3 neutralizing hMAbs 
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recognize distinct quaternary structure epitopes centered at the EDI/II hinge. However, only a 
small fraction (<3%) DENV-specific memory B-cell clones produce strongly neutralizing 
antibodies (83). It has not been clear if epitopes defined using human MAbs are the main 
targets of the polyclonal serum neutralizing antibody response as well. Our studies here 
demonstrate that the DENV2 serotype-specific epitopes targeted by a human MAb, and 
polyclonal immune sera are closely related if not identical. The epitope is a complex, quaternary 
epitope and includes critical residues in EDIII that determine serotype specificity. 
 
The results reveal the fundamental importance of complex quaternary structures on the 
surface of DENV particles for driving potent antibody immune responses. Our results are 
entirely consistent with the 2D22 epitope structure reported by Fibriansah et al (84) 
demonstrating that antibody footprint contains critical contact residues on EDIII of one 
monomer, as well as the fusion loop and BC-loop of EDII on the adjacent monomer, bridging 
across the dimer. The structure also demonstrates that the 2D22 antibody contact sites on EDIII 
are not conserved between serotypes but the contact sites on EDII are highly conserved 
between DENV2 and 4 (84). Thus, the serotype specificity of the 2D22 is determined by EDIII 
and transplantation of this domain into DENV4 was sufficient to create the complete epitope, 
functional epitope. 
 
Dengue vaccines have been challenging to develop because of the need to formulate 
vaccines with four components that simultaneously induce durable neutralizing and protective 
antibodies to each serotype. Without knowing the identity of critical epitopes and regions on 
viruses of the four serotypes targeted by neutralizing and protective polyclonal serum 
antibodies, it has been difficult to dissect tetravalent vaccine responses and efficacy data from 
ongoing clinical trials. Our results demonstrate that the NIH monovalent live attenuated DENV2 
vaccine induces neutralizing antibodies that are similar to those induced by natural infection. 
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The rDENV4/2 chimera is a powerful tool for evaluating antibody site-specific responses 
following infection and vaccine trials. Recombinant DENVs expressing quaternary neutralizing 
antibody epitopes from 2 or more serotypes may lead to simpler and more effective vaccines 
than current tetravalent formulations.  
 
2.6 Materials and Methods 
Virus construction 
Recombinant viruses were constructed using a four-cDNA cloning strategy, the same 
strategy used to create wt DENV infectious clones (Figure 2.2). Patterned after coronavirus 
cDNA clones (85, 86), the DENV-4 genome was subcloned into four separate cDNA plasmids. 
A T7 promoter was introduced into the 5ʹ end of the A fragment, and unique type IIS restriction 
endonuclease cleavage sites are introduced into the 5ʹ and 3ʹ end of each fragment to allow for 
systematic assembly into a genome-length cDNA from which full-length transcripts can be 
derived (85-87). 
 
The EDIII residues from DENV2 were introduced into the DENV4 A subclone by 
replacing E nucleotides 900-1179 with the corresponding nucleotides encoding variant DENV2 
amino acids. The new A fragment with nucleotides from DENV2 was synthesized and inserted 
into pUC-57 plasmid (BioBasic). The new A plasmid and the DENV4 B, C and D plasmids were 
grown in E. coli, purified, digested with corresponding type IIS restriction enzymes, and ligated 
using T4 DNA ligase to create a full-length cDNA dengue viral genome. The full-length cDNA 
was transcribed into genome-length RNAs using T7 polymerase, as previously described by our 
group (85-87). Recombinant RNA was electroporated into BHK-21 cells and cell culture 
supernatant containing viable virus was harvested. Virus was then passaged two times on 
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C6/36 cells, centrifuged to removed cellular debris, and stored at -80°C. Passage 3 represents 
our working stock. 
 
Cells 
Mosquito Ae. albopictus C6/36 cells were grown in MEM (Gibco) media at 32°C. Vero-81 
cells were maintained in DMEM and U937+DC-SIGN were maintained in RPMI at 37°C. 
Medium was supplemented with FBS (10% for Vero-81 and 5% for C6/36 and U937+DC-SIGN), 
which was lowered to 2% after infection. C6/36 and U937+DC-SIGN media was supplemented 
with non-essential amino acids, and U937+DC-SIGN was also supplemented with L-glutamine 
and 2-mercaptoethanol. All media were additionally supplemented with 100 U/mL penicillin and 
100 µg/mL streptomycin. All cells were incubated in 5% CO2 as previously described by our 
group (87). 
 
DENV Type-Specific PCR and RFLP Analysis 
Total RNA was isolated from viral supernatants and used as template for cDNA 
synthesis using standard molecular techniques. Serotype-specific PCR and restriction 
endonuclease analyses were performed on cDNA samples in order to validate purity of the 
recombinant viral preparations (Figure 2.7). 
 
Binding ELISA 
Equal quantities of virus (as previously titrated by ELISA) were captured using either 
mouse anti-DENV MAbs 4G2 and 2H2, or human MAb 1C19. Primary antibodies were diluted 
four-fold starting at concentrations varying from 10 ng/µL-100 ng/µL. Alkaline phosphatase-
conjugated secondary antibodies were used to detect binding of primary antibodies with P-
nitrophenyl phosphate substrate, and reaction color changes were quantified using 
spectrophotometry, as previously described (26).  
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DENV Immune Sera 
De-identified human DENV immune sera were collected from individuals with confirmed 
previous natural DENV infections (Table 2.3). All donations were collected in compliance with 
the Institutional Review Board of the University of North Carolina at Chapel Hill (Protocol #08-
0895). De-identified human immune sera previously collected from adults given the NIH 
monovalent DENV2 vaccine (ClinicalTrials.gov identifier: NCT00920517) was provided by Anna 
Durbin and Stephen Whitehead. All sera was collected following informed consent and approval 
by the Western Institutional Review Board. Non-human primate immune sera were collected 
following experimental DENV infection, and kindly provided by Carlos Sariol (Supplemental 
Table 2). All procedures were reviewed and approved by the Institute’s Animal Care and Use 
Committee at Medical Sciences Campus, University of Puerto Rico (IACUC-UPR-MSC), and 
performed in a facility accredited by the Association for Assessment and Accreditation of 
Laboratory Animal Care (AAALAC) (Animal Welfare Assurance number A3421; protocol 
numbers, 7890108, 7890208, 7890209, and 7890210). 
 
Virus Titration and Focus Reduction Neutralization Test (FRNT) 
One day prior to inoculation, 24-well cell culture plates were seeded with either 5 x 104 
Vero-81 or 1 x 105 C6/36 cells. Prior to inoculation, growth medium was removed. Virus 
titrations were performed by serially diluting virus stocks 10-fold, then incubated for 1 hr at 37°C. 
After incubation, virus dilutions were added to cells for 1 hr at 37°C, then overlaid with 1 mL 1% 
methylcellulose in OptiMEM I (Gibco), supplemented with 2% FBS, 100 U/mL penicillin and 100 
µg/mL streptomycin. After 3-6 days incubation at 37°C, overlay was removed, and cells were 
washed with PBS and fixed in 80% methanol. Plates were blocked with 5% instant milk made in 
PBS, then incubated with anti-E MAb 4G2 and anti-prM MAb 2H2, both diluted 1:500 in blocking 
buffer. Plates then were washed and incubated with HRP-conjugated goat anti-mouse Ab 
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(Sigma), diluted 1:2,500 in blocking buffer. Plates were washed, foci were developed with 
TrueBlue HRP substrate (KPL), and then foci were counted. 
 
For the FRNT assay, either MAbs or sera were diluted four-fold and mixed with ~40 
focus forming units (FFUs) virus, then incubated for 1 hr at 37°C. After incubation, virus and 
MAb or serum dilutions were added to cells for 1 hr at 37°C, then overlay was added and 
processed as above. 
 
Growth Curves 
Either Vero or C6/36 cells were inoculated at a multiplicity of infection (MOI) of 0.01. 
Every 24 hrs, culture supernatant was harvested and centrifuged to remove cellular debris. 
Samples were frozen at -80°C until use. Fresh medium was replaced each day. Viruses were 
titered on their propagating cell type, as described above. U937+DC-SIGN cells were infected at 
an initial infection of 1%, and every 12 hours a sample of cells was harvested, fixed, 
permeabilized, and probed with 2H2 (anti-prM antibody) conjugated to 488. Infected cells were 
quantified using a Guava flow-cytometer (Milipore). 
 
Immunoblotting 
Virus stocks were diluted in PBS, mixed with 4X Laemmli Sample Buffer (Bio-Rad), and 
heated for 10 minutes at 50°C. Samples were run on 12% PROTEAN TGX Gels (Bio-Rad), 
transferred to PVDF membrane and blocked in 5% instant milk in PBS + 0.05% Tween 
overnight at 4°C. Membranes were probed with 0.5 µg/mL anti-E MAb 4G2, 0.5 µg/mL anti-prM 
MAb 2H12 and MAb 5L20 in blocking buffer for 2 hr at 37°C. After washing, HRP-conjugated 
anti-mouse or anti-human secondary antibodies were diluted 1:10,000 in blocking buffer, and 
incubated 1 hr at room temperature. Membrane was exposed to chemiluminescent substrate 
and developed on film. 
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Depletion of DENV2-Specific Antibodies from Immune Sera 
Polyclonal immune sera were depleted of DENV2-binding antibodies as previously 
described (27). Briefly, polystyrene microspheres (Polysciences, 17135) were coated with 
purified DENV2 antigen (Microbix, EL-22-02-001) or BSA control. Immune sera were depleted 
of antibodies by incubating with coated beads for 45 minutes at 37°C for at least three rounds, 
until maximum depletion of antibodies was measured. Depletions of antibodies were confirmed 
by ELISA.  
 
Depletion of rEDIII-Specific Antibodies from Immune Sera 
Polyclonal immune sera were depleted of rEDIII-binding antibodies as previously 
described for rE-binding antibodies (27). Briefly, Dynabeads® (Life Technologies, 14302D) were 
covalently conjugated to DENV2 rEDIII protein following manufacturers protocol or BSA control. 
Immune sera were depleted of antibodies by incubating with conjugated beads for 45 minutes at 
37°C for at least three rounds, until maximum depletion of antibodies was measured. Depletions 
of antibodies were confirmed by ELISA. 
 
ELISA Confirmation of DENV2 or rEDIII Depleted Sera 
ELISA plates were coated directly with either 50ng of DENV2 antigen or 100ng DENV2 
rEDIII per well at 4°C overnight. Plates were blocked as described above. Undepleted, control-
depleted and antigen/rEDIII-depleted sera were diluted 1:40 in blocking buffer and were 
incubated on plates for 1 hour at 37°C. DENV2 or rEDIII reactive antibodies were detected 
using secondary antibody and substrate as described above. 
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Figure 2.1. Design and characterization of rDENV4/2. (A) Amino acid alignment of DENV2 
and DENV4 linear envelope domain III (EDIII) sequence, residues 296-395 of entire E sequence 
(99 aa total). Residues differing between DENV2 and DENV4 are highlighted in yellow. 
Recombinant DENV4 virus containing EDIII from DENV2, designated rDENV4/2, replaces 
differing residues from DENV4 with those from DENV2, highlighted in green (40 aa total). 
Residue generated from escape mutant highlighted in magenta. (B) Crystal structure model of 
DENV2 E protein dimer, with swapped residues colored in green, and DENV2 type-specific MAb 
2D22 escape mutant residue highlighted in magenta. (C) Vero-81 or C6/36 cells were 
inoculated and viral supernatants were collected every 24 hrs and subsequently titered on the 
respective cell type, or 1% of U937+DC-SIGN were infected and total percent infection was 
measured every 12 hours (mean ± s.d.) (D) Immunoblotting of C3/36 grown viruses with anti-E 
and anti-PrM antibodies. E = 55 kD, prM = 21 kD.  
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Figure 2.2. DENV4 infectious clone. Reverse genetics system for manipulating DENV4 
genome. DENV genome was divided into four plasmid cassettes that can be mutated 
individually, ligated together, and electroporated into cells to generate recombinant virus. 
DENV4-A cassette contains the envelope gene, EDIII is highlighted grey. Replacing EDIII 
residues with those from DENV2, in DENV4 backbone, creates rDENV4/2 recombinant virus. A 
total of 58 nucleotide changes were introduced into DENV4-A cassette (highlighted in red). 
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Figure 2.3. Recognition and neutralization of rDENV4/2 virus by DENV-specific 
monoclonal antibodies. ELISA capture assay with (A) cross-reactive MAbs, (B) DENV2-
specific EDIII MAb DVC3.7, (C) DENV4-specific EDIII MAb DV4-E88, (D) DENV4-specific EDI 
MAb 5H2, and (E) DENV2-specific MAb 2D22 (mean ± s.d.). Vero-81 cell based Focus 
Reduction Neutralization Test (FRNT) was performed using (F) DENV2-specific EDIII MAb 
DVC3.7, (G) DENV4-specific EDIII MAb DV4-E88, (H) DENV4-specific EDI MAb 5H2, or (I) 
DENV2-specific MAb 2D22and FRNT50 (concentration of antibody required to neutralize 50% of 
infection) values were calculated (mean ± 95% CI), § = FRNT50 >5 ng/µl 
 
 
-5 -4 -3 -2 -1 0 1
-0.25
0.00
0.25
0.50
0.75
1.00
1.25
1.50
log10(MAb [ng/µl])
O
D
 4
05
DVC3.7
DENV2
DENV4
rDENV4/2
-5 -4 -3 -2 -1 0 1 2
-0.25
0.00
0.25
0.50
0.75
1.00
1.25
1.50
log10(MAb [ng/µl])
O
D
 4
05
DV4-E88
DENV2
DENV4
rDENV4/2
-4 -3 -2 -1 0 1 2
-0.25
0.00
0.25
0.50
0.75
1.00
1.25
1.50
log10(MAb [ng/µl])
O
D
 4
05
2D22
DENV2
DENV4
rDENV4/2
-5 -4 -3 -2 -1 0 1 2
-0.25
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
log10(MAb [ng/µl])
O
D
 4
05
5H2
DENV2
DENV4
rDENV4/2
-5 -4 -3 -2 -1 0 1 2
-0.25
0.00
0.25
0.50
0.75
1.00
1.25
1.50
log10(MAb [ng/µl])
O
D
 4
05
1C19
DENV2
DENV4
rDENV4/2
-5 -4 -3 -2 -1 0 1 2
-0.25
0.00
0.25
0.50
0.75
1.00
1.25
1.50
log10(MAb [ng/µl])
O
D
 4
05
1N5
DENV2
DENV4
rDENV4/2
-5 -4 -3 -2 -1 0 1
-0.25
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
log10(MAb [ng/µl])
O
D
 4
05
1M7
DENV2
DENV4
rDENV4/2
DENV2 DENV4 rDENV4/2
0.001
0.01
0.1
1
10
M
A
b 
[n
g/
µ
l]
2D22 - FRNT50§
DENV2 DENV4 rDENV4/2
0.001
0.01
0.1
1
10
M
A
b 
[n
g/
µ
l]
5H2 - FRNT50§
DENV2 DENV4 rDENV4/2
0.001
0.01
0.1
1
10
M
A
b 
[n
g/
µ
l]
DVC3.7 - FRNT50§
DENV2 DENV4 rDENV4/2
0.001
0.01
0.1
1
10
M
A
b 
[n
g/
µ
l]
DV4-E88 - FRNT50§ §
B" C" D"
G"F"
E"
H" I"
A"
  
 
40 
 
 
Figure 2.4. rDENV4/2 neutralization by human and macaque DENV immune sera. Vero-81 
cell-based Focus Reduction Neutralization Test (FRNT) was performed using (A) primary 
DENV2, (B) primary DENV4, (C) primary DENV1, (D) primary DENV3, and (E) monovalent 
DENV2 vaccine immune sera, and FRNT50 (sera dilution factor required to neutralize 50% of 
infection) values were calculated (mean ± 95% CI). Solid symbols = human sera, empty 
symbols = rhesus macaque sera. Sera that did not block 50% of infection at lowest sera dilution 
factor were assigned a value of 10 (½ the lower limit of detection) for graphing and statistical 
analysis. 
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Figure 2.5. Depletion of DENV2- and rEDIII-binding antibodies. (A) DENV2 immune sera 
were depleted using beads coated with virus (DV2-depleted) or BSA (BSA-depleted) and 
removal of DENV2 binding antibodies was confirmed by ELISA, with wells directly coated with 
DENV2 antigen. (B) DENV2 immune sera were depleted using Dynabeads with DENV2 rEDIII 
(rEDIII-depleted) or BSA (BSA-depleted) and removal of DENV2 rEDIII-binding antibodies was 
confirmed by ELISA, with wells directly coated with rEDIII protein. DT001, IRB019, D031 are 
sera from people exposed to natural DENV2 infections. 250.01.02, 250.01.05 and 250.01.19 are 
sera from people who received the NIH DENV2 vaccine. NHS = normal human serum. 
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Figure 2.6. rDENV4/2 neutralization by DENV2 and rEDIII depleted sera. Vero-81 cell-based 
Focus Reduction Neutralization Test (FRNT) was performed using (A) depleted DENV2 primary 
immune sera and (B) depleted DENV2 vaccine sera. l = sera depleted using Dynabeads®, ▲ = 
sera depleted using polystyrene microspheres. 
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Figure 2.7. Validation of recombinant virus purity. (A) Viruses were grown in C6/36 cells, 
culture supernatant was collected and centrifuged to remove any cellular debris. Viral RNA was 
isolated using QIAGEN QIAamp Viral RNA Miniprep Kit. Serotype specific PCR was run for 35 
cycles, and PCR product was analyzed on 1.5% Ultrapure agarose gel. Control RNA 
(DENV1/DENV2/DENV3/DENV4) and water were run as positive or negative controls. Expected 
product sizes: DENV1 = 205 bp, DENV2 = 539 bp, DENV3 = 455 bp, DENV4 = 401 bp. (B) 
Restriction fragment length polymorphism (RFLP) design to distinguish rDENV4/2 (bottom) from 
parental DENV4 (top). Mutations (represented as asterisks) introduced into DENV4 E gene to 
generate rDENV4/2 disrupted XmnI enzyme restriction site present in DENV4. (C) PCR was 
used to amplify the E gene in both DENV4 and rDENV4/2. PCR products were gel purified and 
digested with XmnI. Digest products were analyzed on 1.5% Ultrapure agarose gel. Expected 
product sizes: full length undigested = 1,031 bp, digested products = 931 bp and 113 bp.  
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Position DENV2 DENV4 AA change 
307 K S positive charge à polar uncharged 
309 V D hydrophobic uncharged à negative charge 
320 I T hydrophobic uncharged à polar uncharged 
325 Q K polar uncharged à positive charge 
329 D A negative charge à hydrophobic uncharged 
331 S A polar uncharged à hydrophobic uncharged 
340 T R polar uncharged à positive charge 
343 E N negative charge à polar uncharged 
345 R E positive charge à negative charge 
353 V S hydrophobic uncharged à polar uncharged 
358 T E polar uncharged à negative charge 
359 E N negative charge à polar uncharged 
360 K T positive charge à polar uncharged 
361 D N negative charge à polar uncharged 
364 V T hydrophobic uncharged à polar uncharged 
382 E G negative charge à hydrophobic uncharged 
383 P N hydrophobic uncharged à polar uncharged 
384 G S hydrophobic uncharged à polar uncharged 
385 Q A polar uncharged à hydrophobic uncharged 
387 K T positive charge à polar uncharged 
389 N H polar uncharged à positive charge 
 
Table 2.1. Summary of amino acid changes in rDENV4/2. Of 40aa residues that were 
changed in recombinant virus, 14 introduced a change of charge. Six residues increase 
negative charge (light red = positive à uncharged, dark red = uncharged à negative), while 
eight residues increase positive charge (light blue = negative à uncharged, dark blue = 
uncharged à positive). Additional residue changes replace hydrophobic amino acids with polar 
amino acids, and vice versa. 
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MAb 
Binding 
Neutralization Epitope information 
Whole 
virus rE rEDIII 
2D22 + - - DENV2 only Quaternary epitope, escape mutant - R323F (EDIII) 
DVC3.7 + + + DENV2 only EDIII lateral ridge 
DV4-E88 + + + DENV4 only EDIII 
5H2 N/A + N/A DENV4 only EDI 
1C19 + + - Cross neutralizing EDII fusion loop and BC loop 
1M7 + + - Cross neutralizing EDII fusion loop region 
1N5 + + - Cross neutralizing EDII fusion loop region 
 
Table 2.2. Summary of MAbs used in this study. 
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 Sera Species 
Date of 
infection Location of infection 
Time since 
infection of  
blood draw 
DENV1 
immune 
sera 
4E6 R.  macaque 5/31/2011 San Juan, Puerto Rico 12 months 
5E5 R.  macaque 5/31/2011 San Juan, Puerto Rico 12 months 
05/262 Human History not known 
07/310 Human History not known 
99/1230 Human History not known 
DENV2 
immune 
sera 
DT001 Human 1996 Sri Lanka 9 years 
IRB019 Human 1997 Thailand 8 years 
DT031 Human 1997 South Pacific 8 years 
DT110 Human 1998 Kuala Lumpur 11 years 
DT134 Human 1984 Yemen 28 years 
BC19 R.  macaque 6/13/2011 San Juan, Puerto Rico 12 months 
3F3 R.  macaque 6/13/2011 San Juan, Puerto Rico 12 months 
06/94 Human History not known 
08/91 Human History not known 
08/90 Human History not known 
DENV3 
immune 
sera 
DT105 Human 2002 Thailand 7 years 
DT118 Human 2009 Nicaragua 12 months 
06/267 Human History not known 
07/327  Human History not known 
DENV4 
immune 
sera 
DT102 Human 2007 Honduras 2 years 
06/301 Human History not known 
07/333 Human History not known 
06/105 Human History not known 
6F8 R.  macaque 6/13/2011 San Juan, Puerto Rico 12 months 
6G0 R.  macaque 6/13/2011 San Juan, Puerto Rico 12 months 
 
Table 2.3. Summary of DENV immune sera used in this study. Non-human primate (R. 
macaque) immune sera described in previous publication (88). 
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Sera ID 
DENV2 virion depletion DENV2 rEDIII depletion 
BSA-
depleted 
(FRNT50) 
DENV2-
depleted 
(FRNT50) 
% loss 
of neut. 
(mean ± 
stdev) 
BSA-
depleted 
(FRNT50) 
rEDIII-
depleted 
(FRNT50) 
% loss of 
neut. 
(mean ± 
stdev) 
DENV2 
infection 
sera 
DT001 147 82 44% 171 131 23% 
IRB019 931 261 72% 372 305 18% 
DT031 1288 721 44% 1493 1140 24% 
DT110 644 76 88% 1718 729 58% 
DT134 235 20 91% 168 129 23% 
08/90 192 64 67% 468 357 24% 
average§  
68% ± 
21%   
28% ± 
15% 
DENV2 
vaccine 
sera 
250.01.02 148 <20 100% 136 228 0% 
250.01.05 478 37 92% 423 331 22% 
250.01.19 318 <20 100% 272 <20 100% 
average  
97% ± 
5%  
41% ± 
53% 
 
All sera average§  
78% ± 
22%  
32% ± 
29% 
 
Table 2.4. Neutralization of rDENV4/2 by human immune sera depleted of DENV2 or EDIII 
binding antibodies. Vero-81 cell-based Focus Reduction Neutralization Test (FRNT) was 
performed sera depleted of DENV2 or rEDIII binding antibodies, and FRNT50 (sera dilution 
factor required to neutralize 50% of infection) values were calculated. % loss of neutralization = 
100 - ((DENV2 or rEDIII-depleted FRNT50/BSA-depleted FRNT50) × 100). § There was a 
statistically significant difference between % loss of neutralization between DENV2 and rEDIII 
depletions by a two-tailed t-test at P<0.05. 
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CHAPTER 3 – Human dengue virus serotype 2 neutralizing antibodies  
target two distinct quaternary epitopes3 
 
3.1 Summary 
Dengue virus (DENV) infection causes dengue fever, dengue hemorrhagic fever and 
dengue shock syndrome. It is estimated that a third of the world’s population is at risk for 
infection, with an estimated 390 million infections annually. Dengue virus serotype 2 (DENV2) 
causes severe epidemics, and the leading tetravalent dengue vaccine has lower efficacy 
against DENV2 compared to the other 3 serotypes. In natural DENV2 infections, strongly 
neutralizing type-specific antibodies provide protection against subsequent DENV2 infection. 
While the epitopes of some human DENV2 type-specific antibodies have been mapped, it is not 
known if these are representative of the polyclonal antibody response. Using structure-guided 
immunogen design and reverse genetics, we generated a panel of recombinant viruses 
containing amino acid alterations and epitope transplants between different serotypes. Using 
this panel of recombinant viruses in binding, competition, and neutralization assays, we have 
finely mapped the epitopes of three human DENV2 type-specific monoclonal antibodies, finding 
shared and distinct epitope regions. Additionally, we used these recombinant viruses and 
polyclonal sera to dissect the epitope-specific responses following primary DENV2 natural 
infection and monovalent vaccination. Our results demonstrate that antibodies raised following 
DENV2 infection or vaccination circulate as separate populations that neutralize by occupying 
domain III and domain I quaternary epitopes. The fraction of neutralizing antibodies directed to 
different epitopes differs between individuals. The identification of these epitopes could 
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potentially be harnessed to evaluate epitope-specific antibody responses as correlates of 
protective immunity, potentially improving vaccine design. 
 
3.2 Author Summary 
Dengue viruses (DENV) are flaviviruses transmitted by mosquitos. There are 
approximately 390 million DENV infections every year, making dengue virus a major global 
public health concern. While there is a recently licensed DENV vaccine, it has low efficacy 
against preventing DENV2 infections. Individuals that are naturally infected with DENV2 
generate neutralizing antibodies that can be protective against reinfection with DENV2. By 
studying three of these neutralizing antibodies, we found that they bind to two different locations 
on the surface of the virus. Additionally we found that most individuals that were naturally 
infected with DENV2, have antibodies circulating in their blood that target both of these regions. 
People who were vaccinated against DENV2 also make antibodies targeting both of these sites, 
suggesting they might also be protected against DENV2 infection. These studies reveal that 
human antibodies against DENV2 target the same two regions across multiple individuals. 
Additionally, for a DENV2 vaccine to be protective, it may be important to elicit antibodies 
directed to these regions as well. 
 
3.3 Introduction 
Dengue virus (DENV) is a single stranded positive sense RNA virus that is transmitted 
by the Aedes mosquito (1). There are four distinct DENV serotypes (DENV1-4), and infection 
results in a range of symptoms, from fever and rash to the more serious dengue hemorrhagic 
fever and dengue shock syndrome. Over a third of the world’s population is at risk for infection, 
and there are an estimated 390 million infections yearly (1). A primary infection with DENV 
results in the induction of serotype cross-neutralizing antibodies which can provide temporary 
serotype cross-protective immunity that is not maintained (64). Over the course of the following 
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year, these cross-reactive neutralizing antibodies wane, leaving individuals susceptible to 
infection by the remaining three heterologous serotypes (12). Serotype-specific neutralizing 
antibodies are maintained in circulation for decades following exposure and may play a critical 
role in providing subsequent protection against the infecting serotype (64, 89, 90). While 
antibodies are known to play a key role in protection against DENV reinfection (91), it has also 
been shown that CD8+ T-cells (92, 93), CD4+ T-cells (94), and other mechanisms of cellular 
immunity are important for protection (95, 96). 
 
The leading DENV vaccines are tetravalent formulations, designed to elicit independent, 
hopefully protective, neutralizing antibodies against all four serotypes simultaneously (97). 
Phase 3 efficacy trials in Asia and Latin America showed that the recently licensed tetravalent 
vaccine, Dengvaxia, had variable efficacy depending on immune status prior to vaccination and 
the serotype of infection (74, 75). In mixed populations of susceptibles and DENV-immunes, 
Dengvaxia was 50-80% efficacious against DENV1, DENV3 and DENV4, but only 35-42% 
against DENV2 (74, 75). Vaccine efficacy was significantly lower in those persons seronegative 
to DENV compared to individuals who were DENV seropositive at the time of vaccination (74, 
75). Moreover, younger vaccinated individuals were hospitalized for DENV more frequently than 
their unvaccinated counterparts, suggesting that poor immunogenicity in naïve subjects might 
place individuals at a greater risk of developing severe disease as antibody levels decline over 
time (4, 63, 98, 99). Indeed, based on long-term follow up data, Dengvaxia is no longer 
recommended for use in DENV-naive individuals (98). The Dengvaxia clinical trials have 
revealed that even individuals with detectable neutralizing antibodies to a particular serotype 
experienced vaccine break-through infections indicating the mere presence of antibodies that 
neutralize infection in cell culture assays is not sufficient for protection (69). Therefore, in 
addition to the level of neutralizing antibodies to each serotype, it is critical to define other 
properties of human antibodies potentially responsible for durable, protective immunity. 
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Importantly, while Dengvaxia contains the structural proteins from DENV, the non-structural 
proteins are from yellow fever virus. It is therefore possible that sufficient T-cell immunity 
towards DENV epitopes was not achieved (4, 100). DENV vaccines that contain DENV non-
structural proteins might generate a more robust T-cell response, and therefore more closely 
resemble a natural DENV infection, which results in a protective immune response (101). 
 
The DENV envelope glycoprotein (E) ectodomain, which is comprised of three domains 
(EDI, EDII and EDIII) is the major target of neutralizing antibodies (5). Two E monomers form a 
dimer in a head-to-tail arrangement, three dimers form a raft, and thirty rafts (180 monomers) 
cover the entire surface of the virus (76). Our group has previously characterized components of 
the antibody response to DENV1, DENV2, DENV3 and DENV4 infection by mapping the 
epitopes of strongly neutralizing human monoclonal antibodies (hMAbs) (21, 27). Importantly, 
many of these strongly neutralizing hMAbs target quaternary structure epitopes that form as the 
envelope glycoprotein is assembled on the virus surface (21, 23, 25, 27, 35, 37, 38, 102). In 
addition, we have demonstrated that we can transplant these quaternary epitopes between 
DENV serotypes and maintain their biological functions (20, 21, 23, 103). While determining the 
properties of individual hMAbs is valuable, complex polyclonal antibody response governs 
protection against subsequent infection. Importantly, the epitope of a single DENV2 serotype-
specific hMAb, 2D22, was shown by our group to be targeted by a large fraction of DENV2 
neutralizing antibodies in many, but not all individuals after recovery from DENV2 infections, 
highlighting the potential role of this epitope in protective immunity (21). Despite this, there are 
additional DENV2 hMAbs that use other epitopes within E, suggesting that there are potentially 
multiple neutralizing antibody epitopes for each serotype. The goals of this study are to identify 
novel neutralizing epitopes in DENV2, to develop robust diagnostic reagents for evaluating 
epitope specific responses with recombinant DENVs (Figure 3.1) and to evaluate the role of 
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these novel and previously described epitopes as target of polyclonal serum antibodies induced 
by natural infections and DENV vaccines.  
 
3.4 Results 
Human monoclonal antibodies target quaternary epitopes on DENV2 
To characterize the epitopes of DENV2 human monoclonal antibodies (hMAbs), we used 
a panel of three DENV2-specific, strongly neutralizing hMAbs (Table 3.1). The hMAbs were 
isolated from two donors infected in geographically distinct locations with different DENV2 
genotypes (104). The three hMAbs, 3F9, 2D22 and 1L12, bound to whole DENV2 virus (Figure 
3.2A). Recently, it has been reported that human antibodies that strongly neutralize DENVs bind 
to quaternary structure epitopes displayed on E homo-dimers or higher order surface structures 
required for virion assembly (21, 25, 27, 105). Consonant with previously published results, 
DENV2 hMAb 2D22 did not bind rE or rEDIII, confirming the quaternary epitope specificity 
(Figure 3.2B and C). HMAb 1L12 was similar and did not bind to rE or rEDIII (Figure 3.2B and 
C). In contrast, hMAb 3F9 weakly bound to rE (Figure 3.2B). Because hMAb 3F9 bound well to 
DENV2 virions and weakly to rE, it is likely that the epitope is dependent on E protein assembly 
into virions for optimal display. In a blockade of binding assay, 2D22 interfered with 1L12 for 
binding to DENV2, suggesting that they recognize proximal or overlapping epitopes on the viral 
envelope (Figure 3.2D). In contrast, 3F9 only partially blocked the binding of 2D22 (Figure 3.2D) 
indicating the two hMAbs recognize distinct epitopes on the viral envelope. 
 
HMAbs 2D22 and 1L12 bind to proximal but distinct epitopes 
The cryo-EM structure of hMAb 2D22 Fab in complex with DENV2 has been solved (38) 
and the footprint of the antibody spans EDIII and EDII of two E molecules forming each homo-
dimer. Although 2D22 did not bind rEDIII (Figure 3.2C), the antibody binds and neutralizes a 
DENV4 virus containing the entire EDIII from DENV2 (rDENV4/2-EDIII) (Figure 3.3) (21, 38). 
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Introducing a single point mutation into this virus (rDENV4/2-EDIII R323G), previously identified 
as a 2D22 escape mutation (27), (Figure 3.3A), resulted in a loss of binding and neutralization 
(Figure 3.3B and C), confirming 2D22 uses the transplanted EDIII region. HMAb 1L12, which 
was isolated from a different donor, showed nearly identical phenotypes, where it gained 
binding and neutralization to rDENV4/2, indicating that it uses EDIII as part of its complex 
quaternary epitope (Figure 3.3D and E). Similarly, the R323G mutation in rDENV4/2 results in 
complete loss of 1L12 binding and neutralization (Figure 3.3D and E). 
 
In addition to binding highly conserved residues in EDII, cryo-EM studies predict that 
hMAb 2D22 interacts with eight (307, 309, 310, 316, 318, 362, 363, 364) surface-exposed 
amino acids in DENV2 EDIII (38), five (307, 309, 316, 362, 364) of which differ between DENV2 
and DENV4. To refine the map coordinates of 2D22 and 1L12 epitopes, we generated a new 
EDIII recombinant virus in which these five amino acids in DENV4 were replaced with those 
from DENV2 (rDENV4/2-EDIII 5aa) (Figure 3.4A). 2D22 was able to partially bind and neutralize 
this virus at high concentrations of antibody (Figure 3.4B and C). Because the gain in function is 
only partial, these data suggest that the epitope requires other critical residues in EDIII for 
maximal binding and neutralization. In contrast, hMAb 1L12 did not bind or neutralize rDENV4 – 
EDIII 5aa (Figure 3.4D and E), suggesting that its epitope overlaps with 2D22 but engages a 
different set of residues on EDIII.  
 
3F9 targets a complex EDI epitope 
Competition assays with 2D22 indicated that 3F9 binds to an epitope that has minimal if 
any overlap with 2D22 or IL12 (Figure 3.2D). To map the epitope of hMAb 3F9, we evaluated its 
binding to a panel of chimeric recombinant DENVs (rDENVs) with alterations in specific 
domains (Figure 3.5A). Our group has previously shown that strongly-neutralizing hMAbs for 
DENV1 and DENV3 use the EDI/II hinge region in their epitope (20, 27, 35, 37). hMAb 3F9 
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bound to a DENV2 virus that had the EDI/II hinge residues replaced with those from DENV4 
(rDENV2/4-EDI/II), suggesting it does not use this region in its epitope (Figure 3.5B). 
Conversely, hMAb 3F9 lost most binding to and neutralization of a DENV2 with 11 of its EDI 
residues replaced with those from DENV4 (rDENV2/4-EDI), suggesting 3F9 uses an epitope 
that contains the replaced residues located in EDI (Figure 3.5B and C). To further characterize 
the 3F9 epitope, we tested its binding to and neutralization of a DENV4 virus that contained 22 
surface-exposed EDI residues from DENV2 (rDENV4/2-EDI) (Figure 3.5D). 3F9 bound to and 
neutralized the EDI transplant virus, confirming EDI as the main target of this hMAb (Figure 
3.5E and F), however gain of binding was not complete, suggesting there are other residues are 
required for maximal binding. Our data underscore the importance of cryo-EM analyses to help 
elucidate the complete 3F9 binding epitope. 
 
In summary, these studies define the location of epitopes recognized by DENV2 type-
specific neutralizing hMAbs 2D22, 1L19 and 3F9. Both 2D22 and 1L19 bind to proximal but 
distinct quaternary epitopes centered on EDIII. hMAb 3F9, on the other hand, binds to an 
epitope on EDI of E protein.  
 
DENV2 polyclonal neutralizing antibodies target epitopes defined by hMAbs 
To determine if epitopes defined using hMAbs were targets of polyclonal serum 
neutralizing antibodies, we first performed competition (blockade of binding) assays with human 
immune sera and hMAbs. Convalescent immune sera from primary DENV2 cases effectively 
blocked the binding of 2D22 to its epitope (Figure 3.6A). Under identical conditions of treatment, 
DENV1 or DENV3 immune sera did not block 2D22 from binding, confirming that primary 
DENV2 infection elicited a 2D22-like serotype-specific antibody response (Figure 3.6A). The 
same DENV2 immune sera also blocked 3F9 from binding to its epitope, whereas control 
DENV1 and DENV3 sera did not (Figure 3.6B). Remarkably, the ratio of antibodies targeting the 
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two epitopes appeared to differ across individuals. Two individuals (DT001 and DT158) were 
more effective at blocking 2D22 binding than 3F9 binding, whereas DT134 and DT155 were 
more effective at blocking 3F9 than 2D22 (Figure 3.6A and B), suggesting these individuals had 
different ratios of antibodies targeting each epitope. DENV2 monovalent vaccine sera also 
blocked 2D22 and 3F9 binding to their respective epitopes (Figure 3.6C and D), indicating that 
natural infection and monovalent DENV2 vaccine-elicited antibodies that targeted these 
epitopes. Interestingly, no DENV2 sera samples were able to completely inhibit either 2D22 or 
3F9 from binding to their epitopes, suggesting a limit in the amount these blocking antibodies 
are present in the sera. 
 
Next, we performed studies to determine if 2D22 and 3F9 epitopes were targets of 
DENV2 neutralizing serum antibodies. Epitope exchanged recombinant viruses not only provide 
an approach to map hMAbs, but they can also be used to quantify epitope-specific neutralizing 
antibodies in immune sera. To measure the amount of neutralizing antibodies targeting 2D22 
and 3F9 epitopes, we evaluated the ability of polyclonal DENV2 immune sera (10 samples) or 
vaccine sera (9 samples) to neutralize rDENV4/2-EDIII (Figure 3.3A) and rDENV4/2-EDI (Figure 
3.5D) viruses. Consistent with previous results (21), a large fraction of DENV2 neutralizing 
antibodies tracked with DENV2 EDIII displayed on the rDENV4/2-EDIII virus (Figure 3.7A). 
Interestingly, most individuals also had neutralizing antibodies that tracked with the DENV2 EDI 
epitope displayed on the rDENV4/2-EDI virus (Figure 3.7A). In some individuals (e.g. DT155) 
there are similar levels of neutralizing antibodies that target both epitopes, whereas in other 
individuals (e.g. DT128) few if any neutralizing antibodies target the 3F9 EDI epitope (Figure 
3.7A). In individuals that received a monovalent DENV2 vaccine, the majority of their 
neutralizing antibodies target EDIII with a much smaller fraction of the response targeting the 
EDI epitope (Figure 3.7B). Overall, there is higher tracking of DENV2 specific responses with 
both the EDIII and EDI epitopes (80% and 54% respectively) in the natural infection sera, as 
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compared with the vaccine sera (69% and 30% respectively), suggesting vaccination elicits a 
slightly different antibody response (Table 3.2). 
 
3.5 Discussion 
People infected with DENVs develop robust and durable antibody responses that 
contribute to protection against re-infection against the homologous serotype; however, rare 
instances of re-infection with the same serotype do occur (106). Antibodies that neutralize 
DENVs in cell-culture assays have been considered to be surrogates of protective immunity in 
vivo. However, this assumption has been challenged by recent results from DENV vaccine 
trials. Most notably, people who received a tetravalent live attenuated DENV vaccine and 
developed neutralizing antibodies experienced DENV2 breakthrough infections (63). 
Breakthrough infections were also documented with the other serotypes despite the presence of 
neutralizing antibodies (63). This landmark vaccine trial has established that the presence of 
cell-culture neutralizing antibodies identified using FRNT assays, is not predictive of protection. 
Indeed, breakthrough DENV infections of vaccinated seronegative children underscore the 
urgency to understand the essential mechanisms of immune protection in DENV. Moving 
forward, we need to define key epitopes on DENVs targeted by neutralizing and potentially 
protective antibodies and develop assays to measure both the level and the molecular 
specificity of neutralizing antibodies. 
 
In this study, we used a panel of hMAbs, human DENV polyclonal immune sera, and 
recombinant DENVs (Figure 3.1) to map the location of epitopes recognized by DENV2 
neutralizing antibodies. First, we used three DENV2 type-specific and strongly neutralizing 
hMAbs to map epitopes. hMAbs 2D22 and 1L12 isolated from different people had similar 
properties and recognized overlapping quaternary epitopes centered on EDIII. Recently 
Fibriansah et. al. determined the cryo-EM structure of 2D22 bound to DENV2 and demonstrated 
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that the footprint of the 2D22 spanned EDIII and EDII of two E proteins forming a single homo-
dimer (38). Our data indicating that 2D22 recognizes an EDIII centered quaternary epitope are 
entirely consistent with the footprint determined by Fibriansah et. al. We suspect that 1L12 also 
binds a similar but not identical epitope because of subtle differences in the binding of 2D22 and 
1L12 noted in this study. These findings highlight the importance of cryo-EM studies with IL12, 
which would provide a more comprehensive view of this larger DENV2 antigenic site. 
Nevertheless, our observation that two individuals infected with different DENV2 genotypes 
produced type-specific neutralizing hMAbs targeting a similar region suggests that EDIII is a 
dominant target of DENV2 neutralizing antibodies. The DENV1, 3 and 4 type-specific, 
neutralizing hMAbs identified to date do not map to the regions defined by 2D22 and 1L12 
indicating that major targets to type-specific neutralizing Abs can differ between serotypes. 
However, several DENV serotype cross-neutralizing hMAbs that bind across the E homo-dimer 
have been described recently (25). While these E dimer-dependent epitope (EDE) hMAbs 
partially overlap with the 2D22 epitope, they recognize patches that are highly conserved 
between serotypes unlike 2D22. 
 
HMAb 3F9 and 1L12, which were isolated from the same person, have distinct epitopes, 
consistent with bivalent recognition of the EDIII and EDI DENV epitopes in most DENV 
polyclonal immune sera. The 3F9 epitopes is centered on EDI at a site that overlaps with known 
DENV1 and DENV4 neutralizing hMAbs (35, 80, 107). Therefore, unlike 2D22, the region 
recognized by 3F9 is targeted by type-specific neutralizing antibodies to other serotypes as well.  
 
Our previous work demonstrated that a majority of the polyclonal antibody response 
following DENV2 infection and vaccination appeared to be directed to a quaternary EDIII 
epitope (21). In some individuals however, neutralization titers did not track as strongly with this 
epitope, suggesting that two or more neutralizing epitopes are targeted disproportionately after 
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primary DENV2 infections. We propose that the EDI epitope defined by the hMAb 3F9 
represents a second major neutralizing epitope on DENV2. Most individuals with naturally 
acquired DENV2 infections contained antibodies targeting both epitopes however some 
individuals targeted only one epitope, or had a skewed response. Similar results were observed 
in DENV2 vaccinated individuals, where there were antibodies targeting each epitope, however 
the overall response is dominant to the EDIII epitope. Overall, there was a higher response of 
antibodies tracking with the EDIII than the EDI epitope in both the natural infection and 
vaccinated sera (Table 3.2). Interestingly, some individuals had complete neutralizing antibody 
responses tracking with both epitopes, suggesting that they potentially generated redundant 
populations of antibodies. Generating populations of antibodies directed to different regions on 
E could be an important component of an effective antibody response. Viruses can mutate to 
escape antibody pressure, but simultaneously escaping antibody pressure to multiple sites on E 
would be more challenging (108, 109). As some individuals appear to mount preferential 
responses to one site or the other after natural infection or vaccination, it is possible that strains 
with natural variation within one of these epitopes may allow for repeat or breakthrough DENV2 
infections.  
 
Without a clear understanding of what constitutes a protective DENV antibody response 
to each serotype, it is challenging to evaluate current DENV vaccines. By defining the epitopes 
targeted by DENV2 hMAbs and polyclonal sera, we hope to determine if there are antibody 
based correlates of protection and use these to evaluate current vaccines in the pipeline, and 
inform the design of next-generation vaccines. Using recombinant DENVs that contain both gain 
of function and loss of function epitopes, we can rapidly map in high-throughput assays the 
epitopes of large panels of hMAbs, prioritizing targets for crystallographic studies and 
downstream analyses. 
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3.6 Methods 
Virus Construction 
Recombinant viruses were constructed using a four-cDNA cloning strategy. The DENV 
genome was divided into four fragments, and subcloned into separate cDNA plasmids with 
unique type IIS restriction endonuclease cleavage sites at the 5’ and 3’ ends of each fragment. 
A T7 promoter was introduced into the 5’ end of the A fragment. Plasmid DNA was grown in 
Escherichia coli cells, digested with the corresponding enzymes, gel purified, ligated together 
with T4 DNA ligase and transcribed with T7 polymerase to generate infectious genome-length 
capped viral RNA transcripts. RNA was electroporated into C6/36 cells, cell culture supernatant 
containing virus was harvested and passaged onto C6/36 cells to generate a passage one virus 
stock. 
 
Cells 
C6/36 cells (ATCC CRL-1660) were grown in Gibco minimal essential medium (MEM) at 
32°C. Vero-81 cells (ATCC CCL-81) were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) at 37°C. Media were supplemented with fetal bovine serum (FBS) (10% for Vero-81 
and 5% for C6/36) which was lowered to 2% after infection. C6/36 media were supplemented 
with nonessential amino acids. All media were additionally supplemented with 100U/ml 
penicillin, 100µg/ml streptomycin and 0.25µg/ml Amphotericin B. All cells were incubated in 5% 
CO2. 
 
Ethics Statement 
Human dengue immune sera used in this study were obtained from a previously 
described Dengue Traveler collection at University of North Carolina, and were all primary 
DENV2 natural infections (21, 23, 27). Vaccine sera were obtained from individuals who 
received a live-attenuated monovalent DENV2 vaccine as developed by the US National 
  
 
60 
Institutes of Health (NIH) and were provided by Anna Durbin and Stephen Whitehead. All 
human sera samples were obtained under Institutional Review Board approval and were 
anonymized.  
 
Virus Titration and Immunostaining 
One day prior to inoculation, 24-well cell culture plates were seeded with either 5x104 
Vero-81 cells. Virus stocks were serially diluted 10-fold then added to cells (after growth media 
was removed) for one hour at 37°C. After incubation, cells were overlaid with 1% 
methylcellulose in OptiMEM I (Gibco) supplemented with 2% FBS, nonessential amino acids 
and 100U/ml penicillin, 100µg/ml streptomycin and 0.25µg/ml Amphotericin B, and incubated at 
32°C. After four days incubation, overlay was removed, cells were washed with phosphate-
buffered saline (PBS) and fixed in 80% methanol. Cells were blocked in 5% non-fat dried milk 
(blocking buffer) then incubated with anti-prM MAb 2H2 and anti-E MAbs 4G2 diluted in blocking 
buffer. Cells were washed with PBS, then incubated with horseradish peroxidase (HRP)-
conjugated goat anti-mouse antibody (Sigma) diluted in blocking buffer. Plates were washed 
and foci were developed using TrueBlue HRP substrate (KPL). 
 
Binding Enyzme-Linked Immunosorbent Assay (ELISA) 
For whole DENV ELISA, plates were coated with 100ng/well mouse MAb 4G2 and 2H2 
overnight at 4°C. Plates were washed with Tris-buffered saline with 0.05% Tween (TBST) and 
blocked in 3% non-fat dried milk in TBST (blocking buffer), and equal quantities of virus (as 
previously titrated by ELISA using cross-reactive polyclonal DENV immune sera) were added 
and incubated for 1 hour. For rE and rEDIII ELISA, plates were directly coated with protein and 
incubated. Plates were washed and primary human MAbs were diluted in blocking buffer and 
added to plate for 1 hour. Plates were washed and alkaline phosphate (AP)-conjugated 
secondary antibodies were added for 1 hour. Plates were washed, developed using p-
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nitrophenyl phosphate substrate and color changes were quantified by spectrophotometry. 
Assays were developed until OD values were within linear range of the assay, therefore 
absolute OD values may vary between graphs. All binding assays are based on two 
experiments performed in duplicate.  
 
Blockade of Binding Assay 
Plates were coated with antibody, blocked, and virus was captured as described above. 
DENV polyclonal immune sera were depleted of cross-reactive antibodies as described 
previously (23). Briefly, sera were incubated with beads coated with purified DENV4 antigen, 
then beads were pelleted to removed cross-reactive antibodies bound to bead:antigen 
complexes. Cross-reactive depleted sera were then diluted 1:10 in blocking buffer and 
incubated for 1 hour. Plates were washed and alkaline phosphate (AP)-conjugated 2D22 
(100ng/well) or 3F9 (50ng/well) were added for 1 hour. Plates were developed as described 
above. Percent blockade was calculated as follows = (100-[OD of sample/OD of negative 
control]*100). Blockade of binding assays are based on two experiments performed in duplicate. 
 
Focus Reduction Neutralization Test 
For the focus reduction neutralization test (FRNT), hMAbs were diluted 4-fold and mixed 
with ~45 focus-forming units (FFU) of virus, and incubated for 1 hour at 37°C. After incubation, 
virus:hMAb mixture was added to Vero-81 cells for 1 hour at 37°C or C6/36 cells for 1 hour at 
32°C, then overlay was added and cells were incubated and fixed and stained as described 
above. Foci were counted and FRNT50 titers were calculated as the concentration of antibody or 
sera dilution factor required to neutralize 50% of the virus. Neutralization assays are based on 
two (HMAbs) or one (immune sera) experiments performed in triplicate. 
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Figure 3.1. Sequences of rDENVs. Amino acid sequences of WT and rDENVs used to map 
antibody epitopes. 
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Figure 3.2. DENV2 serotype-specific hMAbs use multiple quaternary epitopes. DENV2 
hMAbs 2D22, 1L12 and 3F9 were assessed for their ability to bind whole DENV2 virions (A), 
DENV2 rE (B), and DENV2 rEDIII (C). Positive control (+) hMAb is DVC10.16, a DENV2 hMAb 
that uses a simple A-strand epitope contained entirely within EDIII and 5J7 is a DENV3 
serotype-specific hMAb as a negative control (-). (D) Blockade of binding assay where hMAbs 
2D22, 1L12 or 3F9 were assessed for their ability to block 2D22-AP from binding to DENV2.  
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Figure 3.3. HMAbs 2D22 and 1L12 use EDIII in their epitopes. (A) rDENV4/2-EDIII is DENV4 
virus containing entire EDIII from DENV2. rDENV4/2-EDIII R323G is rDENV4/2 virus with single 
point mutation at residue 323. 2D22 and 1L12 were assessed for their ability to bind (B and D) 
and neutralize (C and E) recombinant DENVs in ELISA binding assays and Vero-81 Focus 
Reduction Neutralization Tests (FRNT). Dotted line in ELISA represents the background signal. 
FRNT50 represents the concentration of antibody required to neutralize 50% of infection. # = 
virus was not neutralized at highest concentration of hMAb tested (5ng/µl). 
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Figure 3.4. HMAbs 2D22 and 1L12 use different critical residues in their epitopes. (A) 
rDENV4/2-EDIII 5aa is a DENV4 virus with five EDIII residues from DENV2. 2D22 and 1L12 
were assessed for their ability to bind (B and D) and neutralize (C and E) recombinant DENV in 
ELISA binding assays and Vero-81 Focus Reduction Neutralization Tests (FRNT). Dotted line in 
ELISA represents the background signal, determined as the OD value of wells containing all 
reagents except for viral antigen. 
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Figure 3.5. HMAb 3F9 use an epitope contained within EDI. (A) rDENV2/4-EDI/II is DENV2 
virus containing EDI/II hinge region residues from DENV4. rDENV2/4-EDI is DENV2 virus 
containing EDI residues from DENV4. 3F9 was assessed for its ability to bind (B and E) and 
neutralize (C and F) recombinant DENVs in ELISA binding assays and Focus Reduction 
Neutralization Tests (FRNT) in Vero-81 cells (C) or C6/36 cells (F). Dotted line in ELISA 
represents the background signal. (D) rDENV4/2-EDI is DENV4 virus containing EDI residues 
from DENV2. 
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Figure 3.6. DENV2 polyclonal antibodies target EDIII and EDI epitopes. Blockade of binding 
assay where DENV2 natural infection immune sera (A, B) or DENV2 monovalent vaccine sera 
(C, D), were assessed for their ability to block 2D22-AP (A, C) or 3F9-AP (B, D) from binding to 
their respective epitopes on DENV2. DENV immune sera were depleted of cross-reactive 
antibodies prior to blockade assay. 
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Figure 3.7. DENV2 polyclonal neutralizing antibodies target two distinct epitopes. DENV2 
immune sera (A) and monovalent vaccine sera (B) were evaluated for their ability to neutralize 
WT and rDENV in C6/36 Focus Reduction Neutralization Tests (FRNT). Dotted line represents 
limit of detection (20), samples with no neutralization were plotted at one half the limit of 
detection (10). Y-axis indicates sera dilution factor required to neutralize 50% of virus. 
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Donor Infection Location 
Infecting 
Genotype 
Infection 
Year MAb 
Neut50 (µg/ml) 
DENV
1 
DENV
2 
DENV
3 
DENV
4 
IRB019 Thailand Asian 1997 2D22 >10 0.08 >10 >10 
DT001 Sri Lanka Cosmoplitan 1996 
1L12 >10 0.4 >10 >10 
3F9 >10 0.03 >10 >10 
 
Table 3.1. DENV2 monoclonal antibodies. Virus was isolated from subject DT001, sequenced 
and found to be part of the cosmopolitan genotype (110). Subject IRB019 was infected in 
Thailand in 1997 when the DENV2 Asian genotype strain was circulating in the region. 
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FRNT50 [Sera Dilution Factor] α 		 Percent tracking with 
β 
Type Sera ID DENV2 DENV4 rDENV4/2 -EDIII 
rDENV4/2 
-EDI 		 EDIII EDI 
Natural 
Infection 
Sera 
DT001 228 --- 431 385 		 100 100 
DT110 2286 97 3170 2004 		 100 88 
DT128 313 --- 158 --- 		 51 0 
DT134 809 22 550 217 		 65 24 
DT155 208 --- 263 320 		 100 100 
DT158	 740 --- 1030 372 		 100 50 
DT242	 410 --- 553 175 		 100 43 
ss06/94	 153 --- 65 43 		 42 28 
ss08/91	 107 --- 188 70 		 100 66 
ss08/90	 154 --- 65 62 		 42 41 
Average	
(±SD)	         		 80% ± 27 54% ± 34 
   		         		     
DENV2 
Monovalent 
Vaccine Sera 
250.10 675 32 267 92   35 9 
250.11 783 69 566 62   63 0 
250.15 473 79 621 169   100 19 
250.05 144 --- 232 47   100 33 
250.02 144 29 144 36   80 5 
250.03	 199 --- 108 77   55 39 
250.07	 80 --- 58 41   72 52 
250.13	 743 109 1396 1871   100 100 
250.24	 348 38 90 83   15 13 
Average	
(±SD)	         		 69% ± 30 30% ± 31 
 
Table 3.2. Percent polyclonal neutralization tracking with each epitope. α FRNT50 [Sera 
Dilution Factor] were calculated as the sera dilution factor required to neutralize 50% of the 
virus, extrapolated from Figure 3.7. β Percentage calculated as = (rDENV4/2-EDIII FRNT50 – 
DENV4 FRNT50)/(DENV2 FRNT50) x 100, and = (rDENV4/2-EDI FRNT50 – DENV4 
FRNT50)/(DENV2 FRNT50) x 100. 
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CHAPTER 4 – Human DENV2-specific antibody response following  
tetravalent dengue vaccination 
 
4.1 Introduction 
Dengue vaccines 
An effective dengue virus (DENV) vaccine should result in an immune response that is 
protective against infection to each of the four DENV serotypes. The leading DENV vaccines 
are live attenuated, tetravalent formulations designed to elicit an independent, robust antibody 
response to each serotype simultaneously. However, replication interference between the 
different vaccine components, and immune dominance has led to an unbalanced or skewed 
response (111). Individuals with an unbalanced response might may be poorly protected against 
some serotypes. These individuals might be at increased risk for severe disease following a 
natural DENV infection, through mechanisms of antibody dependent enhancement (ADE). 
 
Sanofi Pasteur’s live-attenuated, tetravalent DENV vaccine, Dengvaxia, is based on the 
yellow fever 17D vaccine. The chimeric vaccine, CYD-TDV (chimeric yellow fever dengue-
tetravalent dengue vaccine) contains the prM and E structural components of each DENV 
serotype, in an attenuated yellow fever virus vaccine backbone (YFV17D) (68). The vaccine 
contains equal amounts of each serotype component, and is given in three doses, six months 
apart. Preclinical testing of CYD-TDV in vitro, and in vivo in both mice and non-human primate 
models, showed that the vaccine was both safe and immunogenic (112-114). Early phase I and 
II clinical trials evaluated safety and immunogenicity in flavivirus-naïve or pre-immune healthy 
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individuals (toddlers to adults) before the vaccine was moved into larger phase IIb and III trials 
(115-119).  
 
Antibody response to Dengvaxia vaccination 
Early studies evaluated the neutralizing antibody responses to vaccination using cell 
culture based assays. The vaccine stimulated broad neutralizing responses against all four 
serotypes (115-118), however the properties of these antibodies, such as their serotype-
specificty, was not known. Additionally, flavivirus pre-immune individuals had higher, and 
broader neutralizing responses (119). More recent work has looked at evaluating the molecular 
specificity of antibodies induced by the Dengvaxia vaccine in healthy trial participants (22). 
Flavivirus-naïve healthy adults vaccinated with three doses of Dengvaxia, generated a robust 
cross-neutralizing response against all four serotypes, with highest neutralization titers to 
DENV4, followed by DENV2, DENV3 and DENV1 (22). These results were consonant with 
Sanofi’s clinical testing of their vaccine neutralizing antibody responses, and promising that the 
vaccine would have high efficacy in phase III trials.  
 
Cell-culture based neutralization assays however, cannot distinguish between 
neutralization due to serotype-specific neutralizing antibodies, and cross-reactive antibodies. 
Additionally, it is thought that weakly neutralizing cross-reactive antibodies can overestimate 
neutralization capacity via cell culture assays, whereas they are known to not be protective in 
people. Using depletion-based assays, the fraction of the neutralization response attributable to 
serotype-specific antibodies and cross-reactive antibodies can be calculated, by specifically 
removing certain populations of antibodies from the serum. Briefly, beads are coated with 
purified DENV, incubated with polyclonal immune sera, and then centrifuged to pellet bead-
DENV-Ab complexes, selectively removing any antibodies that bind to the virus (70). For 
example, to determine the contribution of DENV1 serotype-specific antibodies to total 
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neutralization of DENV1, beads are coated with a mix of DENV2, DENV3 and DENV4 antigen, 
which will bind serotype-specific antibodies targeting DENV2, DENV3 and DENV4, as well as all 
cross-reactive antibodies, leaving only DENV1 serotype-specific antibodies in the serum 
sample. We can then measure neutralization of DENV1 with undepleted and depleted sera, and 
calculate the percent of serotype-specific antibodies contributing to neutralization.  
 
When these experiments and analyses were performed with Dengvaxia vaccine sera, it 
was discovered that DENV4 neutralization was primarily due to serotype-specific antibodies, 
whereas DENV1, DENV2 and DENV3 were primarily targeted by cross-reactive antibodies (22). 
Vaccination of individuals who were flavivirus pre-immune, resulted in higher neutralization titers 
against all four serotypes, predominantly due to boosting of cross-reactive antibodies (22). 
Additionally, pre-immune individuals had higher post-vaccination neutralization titers compared 
with flavivirus naïve individuals (22). These analyses indicate that in naïve individuals, the 
vaccine induces a robust DENV4 serotype-specific antibody response that should be protective 
in people. The highly cross-reactive response against serotypes DENV1, DENV2, and DENV3 
might not be sufficient from protection following natural exposures. Importantly, in flavivirus pre-
immune individuals, the vaccine appears to boost a cross-reactive response, similarly to a 
secondary DENV infection, which should be protective against natural infection. 
 
Results from Dengvaxia phase II/III trials 
A proof-of-concept phase IIb clinical efficacy trial (CYD23b) was performed in 
schoolchildren aged 4-11 in Thailand to evaluate vaccine efficacy (120). It was found that 
overall vaccine efficacy was ~30%, but differed greatly by serotype, with the worst protection 
against DENV2 (3.5% vaccine efficacy), which dominated during the trial (2.6% total attack rate, 
43% of breakthrough infections were DENV2) (120). Importantly, cell culture neutralization titers 
following the third dose, were high and similar across all four serotypes (highest titers against 
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DENV2), revealing that the mere presence of cell-culture based neutralizing antibodies is not 
predictive of, nor sufficient for protection from natural infection (120). Despite the low overall 
vaccine efficacy, and essential failure against DENV2, the vaccine was determined to be well-
tolerated, with no evidence of safety signals one year following the third dose. This study did 
however, highlight the discordance between cell-culture based neutralization titers and 
protection, and the highly variable vaccine efficacy based on DENV serotype. 
 
Following the moderate success of the phase IIb trial, large-scale phase III trials were 
performed in Asia in children aged 2-14 (CYD14) and in Latin America in individuals aged 9-16 
(CYD15). Both trials consisted of an active phase for one year following the third vaccine dose, 
followed by an additional four years of hospital phase. Overall vaccine efficacy was moderate 
against all four serotypes, ~55% and ~60% for CYD14 and CYD15 respectively (68). 
Importantly, similar to results from the CYD23b trial, vaccine efficacy varied highly by serotype. 
Vaccine efficacy reached ~80% efficacy against DENV4 in CYD15, but efficacy against DENV2 
was always the lowest in both CYD14 (35%) and CYD15 (42%) (4, 68). The observed attack 
rates were slightly higher than CYD23b (4.7% and 2.9% for CYD14 and CYD15 respectively) 
but unlike CYD23b, serotype distribution of breakthrough infections was evenly balanced 
between the four serotypes. Therefore, the poor efficacy against DENV2 seen in CYD14 and 
CYD15 was not driven by a disproportionate amount of circulating DENV2 during these trials; 
only 23% (CYD14) and 21% (CYD15) of breakthrough infections were DENV2 (68).  
 
Analyses of sera from CYD14 and CYD15 vaccinated individuals revealed that the 
vaccine elicited neutralizing antibodies to all four serotypes as determined by plaque reduction 
neutralization assays (4, 63, 68, 69). Importantly, higher neutralizing antibody titers from month 
13 (one month following the third vaccine dose) correlated with a higher vaccine efficacy and 
significantly lower risk of virologically confirmed DENV (VCD) infection (69). Individuals with 
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high levels of neutralizing antibodies however, still experienced breakthrough infections for all 
four serotypes, suggesting that the presence of neutralizing antibodies are not sufficient for 
protection (69). Additionally, higher neutralizing antibody titers strongly correlate with baseline 
serostatus, potentially driving the higher vaccine efficacy seen in individuals who were pre-
immune to DENV (68). In all trials, vaccine efficacy was lowest in individuals who were DENV-
naïve prior to vaccination. These results raise the important distinction between the CYD-TDV 
boosting pre-existing immunity in baseline seropositive individuals, leading to high vaccine 
efficacy in this population, versus the ability of CYD-TDV to elicit a protective immune response 
in naïve individuals (4, 68). 
 
In DENV endemic countries, age is a strong correlate for previous DENV infection. 
Results from CYD14 and CYD15 analyses revealed that the vaccine performed worse in both 
younger and naïve populations (68). Additionally, it was found that in CYD14, there was a 7.45 
relative risk for hospitalization for VCD in younger children, suggesting that Dengvaxia 
sensitizes seronegatives to more severe disease in subsequent natural infection (63, 121). 
These results revealed that in this population, receiving the vaccine put individuals at a 
significantly higher risk for more severe disease upon natural infection compared to non-
vaccinated controls (121). These results are supported by the hypothesis that the vaccine elicits 
weakly neutralizing cross-reactive antibodies (22), and upon natural infection, these antibodies 
enhance infection and disease via antibody dependent enhancement (ADE) mechanisms (4, 
121, 122). While these results fully support the hypothesis that, baseline immune status, and not 
merely young age, is a crucial factor for vaccine success or risk, Dengvaxia was licensed for 
use in individuals over the age of 9, regardless of serostatus (123). Dengvaxia was licensed in 
19 countries, the Philippines government bought 3 million doses of Dengvaxia, and intended to 
vaccinate one million 9-year old school children. By December of 2017, over 800,000 children 
had received at least one dose of Dengvaxia (122).  
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Unfortunately, with additional years of follow-up study of CYD14 and CYD15, it was 
revealed that in certain populations, namely DENV-naïve individuals, Dengvaxia resulted in 
increased risk of more severe disease and hospitalization following natural infection (98, 99, 
124). Importantly, these results were in agreement with short-term follow up results (63, 68), 
revealing that Dengvaxia sensitizes seronegatives to enhanced disease, regardless of 
vaccination age. These results prompted the WHO and Sanofi to change their 
recommendations for the vaccine to only be used in individuals over 9 years of age who are 
baseline seropositive to DENV (98, 99, 124). In the Philippines there are multiple reports of 
deaths of Dengvaxia-vaccinated children after subsequent natural DENV infection; the 
Philippines Department of Heath has formed a committee to investigate whether the deaths 
were linked to Dengvaxia vaccination (122).  
 
Outstanding Research Questions 
Early results from Dengvaxia’s phase III trials suggested that an effective DENV vaccine 
was possible, however the longer-term follow-up results have greatly complicated this story. 
Importantly, these trial results reveal that our current cell-culture based antibody neutralization 
titer correlates of protection, are insufficient to estimate protective immunity (66, 67). 
Additionally these results reveal that currently used neutralization assays, do not distinguish 
between strongly and weakly neutralizing serotype-specific antibodies, which are known to be 
important for protection, and weakly cross-neutralizing antibodies, which are known to lead to 
ADE in people (70, 89, 125). Evaluating the quantity and quality of serotype-specific antibody 
responses to each of the four serotypes following vaccination, could improve, or provide more 
accurate antibody based metrics of protection. While these analyses are critical for evaluating 
responses to all four serotypes, vaccine efficacy in all trials was dramatically worst against 
DENV2, so the subsequent approach will focus on that serotype. 
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4.2 Approach and Results 
Determine quality of Dengvaxia induced DENV2 neutralizing antibodies 
It is known that natural DENV infection results in a population of strongly neutralizing 
serotype-specific antibodies, which play a critical role in protection. Previous work revealed that 
vaccination of healthy, flavivirus-naïve individuals, resulted in high DENV2 neutralization titers, 
but that neutralization was predominantly due to cross-reactive antibodies (22). It is possible 
that there is a certain percentage or titer of DENV2 serotype-specific antibodies required to 
protect against infection. To test this hypothesis, we are performing depletion assays using the 
following samples; 1) DENV2 natural infection sera, 2) CYD14/CYD15 month 13 sera from 
vaccinated individuals. Within the CYD14/15 collection, we will evaluate i) samples with DENV2 
breakthrough infections, or ii) samples from matched vaccinated controls without breakthrough 
infections. While we will not know if individuals without DENV2 breakthrough infections were 
exposed and protected, or simply unexposed, we can evaluate any qualitative trends between 
the groups. By performing depletion assays, we can determine if there are any trends between 
percentage or absolute titer of DENV2 serotype-specific and breakthrough infection or not. We 
predict that, consistent with analyses from earlier trials (22), the vaccine will elicit low levels of 
DENV2 serotype-specific antibodies in both breakthrough and non-breakthrough individuals, in 
comparison to the high levels we see with DENV2 natural infection.  
 
Pilot studies using depletion and neutralization assays with sera from vaccinated naïve 
healthy adults allow us to calculate DENV2 serotype-specific neutralization titers, and percent of 
DENV2 neutralization from serotype-specific antibodies. Vaccine sera were either control 
depleted with BSA, or depleted of cross-reactive antibodies using DENV4, and neutralization 
assays are performed against DENV2 and DENV4 viruses. Using a primary DENV2 infection 
sera as a positive control, we can calculate the relative loss of neutralization due to cross-
reactive antibodies, and find that up to 60% of the total neutralization of DENV2 comes from 
  
 
78 
serotype specific antibodies (Figure 4.1). Using these same assays with vaccine sera from 
naïve individuals, we find a range of absolute DENV2 neutralization titers (FRNT50 of 149-398) 
and percent of DENV2 serotype-specific antibodies (18-62%) (Figure 4.2). 
 
We were curious to see if there was a potential correlation between absolute DENV2 
neutralization (by serotype-specific and cross-reactive antibodies) and percent serotype-specific 
neutralization. We see that there is no correlation however, and that despite absolute titers 
being similar, there is a large range of percent serotype-specific neutralization (Figure 4.3). 
Interestingly, the sample with the lowest titer (CYD17-52) had the highest percentage of 
serotype-specific antibodies (62%), which is similar to the percentage seen in a DENV2 natural 
infection (Figure 4.1).   
 
Determine epitopes targeted by DENV2 serotype-specific antibodies 
Serotype-specific antibodies can be further characterized based on the types of epitopes 
they target. Polyclonal immune sera can contain many antibodies targeting simple or linear 
epitopes. Depleting sera of these antibodies has minimal impact on total neutralization, 
revealing that these antibodies contribute little towards the robust neutralization capacity of 
polyclonal immune sera (27, 28, 65). Conversely, antibodies targeting quaternary epitopes, 
spanning either envelope domains, monomers or dimers, and present only on the intact virion, 
provide the strong neutralization by serotype-specific antibodies in polyclonal immune sera (27). 
We have identified and characterized two distinct, quaternary DENV2 epitopes (21, 126). One of 
these epitopes, defined by the human DENV2 monoclonal antibody (MAb) 2D22, spans across 
EDIII or one monomer into EDII fusion loop region of the neighboring monomer (38). The other 
epitope, defined by MAb 3F9 uses a quaternary epitope on EDI (126). The epitopes defined by 
these antibodies, are targeted by strongly neutralizing DENV2 serotype-specific polyclonal 
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antibodies from individuals naturally infected with DENV2, and are therefore, thought to 
important epitopes to target for protection (126).  
 
Importantly, these epitopes are transplantable between serotypes, and have both been 
moved into a DENV4 virus (126). These viral reagents allow us to measure the amount of 
DENV2 serotype-specific antibodies targeting these epitopes in polyclonal immune sera. Using 
these viruses, and the three types of sera samples described above (natural infection and 
vaccinees with DENV2 breakthrough infection or without) we can measure the amount and 
percentage of DENV2 serotype-specific antibodies targeting each of these two epitopes. It is 
already known the individuals with DENV2 natural infections target both epitopes, albeit the ratio 
targeting each varies across individuals (126). These analyses will allow us to determine if 
Dengvaxia elicits antibodies targeting either or both epitopes, and whether there are any trends 
between epitope and breakthrough or protection. 
 
Using the same samples, we were able to perform neutralization assays using a 
rDENV4 virus containing EDIII from DENV2, which we’ve previously shown to track with the 
human monoclonal antibodies 2D22, 1L12, and polyclonal DENV2 neutralizing antibodies (21, 
126). We find that all of the DENV2 serotype-specific neutralization tracks with this epitope 
(Figure 4.4), despite the large range of percent serotype-specific antibodies. This result is 
consistent with DENV2 natural infection sera (21, 126), suggesting that while the vaccine might 
elicit lower levels of serotype-specific antibodies, they appear to target the same region.  
 
Impact of antigenic diversity on vaccine response 
Within each DENV serotype, there is genetic and antigenic diversity resulting in multiple 
distinct genotypes (104, 127). In natural DENV infection, it is thought that the serotype-specific 
antibody response is broad enough, that it would protect against reinfection with any genotype 
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within the homologous DENV serotype (104, 127). There is growing evidence however, that 
antigenic diversity within serotypes might be great enough to escape pre-existing immunity 
(128). Additionally, reinfection with homologous serotype is rare, but does occasionally occur, 
especially after clade replacements altering the circulating genotype (106). An effective DENV 
vaccine would not only need to elicit strongly neutralizing antibodies to each serotype, but the 
neutralizing response would need to have enough breadth to neutralize all circulating DENV 
genotypes, not just the genotype of the vaccine strains.  
 
It was proposed that the poor efficacy of Dengvaxia could be partially due to circulating 
genotypes that differ from the vaccine strains (4). Early evaluation of CYD-TDV responses 
tested the ability of vaccinated non-human primate sera to neutralize a large panel of DENVs, 
representing many of the genotypes within each serotype (129). Importantly, they found that 
vaccine sera neutralizes the majority of DENV stains tested, however they saw the most 
variability within DENV2, with only half of strains efficiently neutralized within 95% confidence 
interval of the assay (129). This result suggested that there is broad genotypic breadth within 
the antibody response to vaccination, but importantly, these assays do not distinguish between 
neutralization by serotype-specific antibodies and cross-reactive antibodies. Therefore, it is 
possible the breadth of response they see (to all serotypes and genotypes), might be driven by 
a highly cross-reactive antibody response. 
 
In Dengvaxia phase III trials, viruses from all breakthrough infections (from both 
vaccinees and placebos) were isolated and sequenced to determine the genetic epidemiology 
of these trials (130). For DENV2, the circulating genotypes were Asian I and Cosmopolitan 
(CYD14), and Asian/American (CYD15). The circulating Cosmopolitan genotype had the most 
amino acid diversity (97.4% conservation) from the vaccine strain (Asian I), whereas the 
circulating Asian/American and Asian I strains were more similar (97.9% conservation for both) 
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(130). Considering these subtle differences in circulating strain sequences, the vaccine had no 
observable significant differences in vaccine efficacy against different genotypes (130). This is 
in great contrast to DENV4, where the vaccine works significantly better against vaccine-
matched circulating strains (DENV4 genotype II) versus against vaccine mismatched strains 
(DENV4 genotype I) (130). These results are in line with analyses that determined the quality of 
antibody responses following vaccination; cross-reactive neutralizing antibodies drive DENV1-3 
neutralization, whereas DENV4 neutralization is primarily due to serotype-specific neutralizing 
antibodies (22). Antibodies that recognize multiple serotypes are less likely to be impacted by 
amino acid diversity within each serotype, whereas serotype-specific antibodies would be more 
sensitive to genotypic variation.  
 
Given that experiments determining breadth of vaccine sera neutralization were 
performed with sera containing both cross-reactive and serotype-specific antibodies, it is 
possible that DENV2 serotype-specific antibodies are more sensitive to genotypic variation. To 
test this hypothesis, we will use DENV2 natural infection sera (as a control) and CYD14/15 
vaccine sera from both individuals with and without DENV2 breakthrough infections. We will 
deplete sera of cross-reactive antibodies, so only DENV2 serotype-specific neutralizing 
antibodies are remaining, and test ability of depleted sera to neutralize a large panel of DENV2 
genotypic variants. We suspect that undepleted will be highly cross-neutralizing to all strains, 
unlike DENV2-specific sera, which might show genotypic-specific variation, likely with the 
highest neutralization titers against Asian I vaccine-matched strains.  
 
As a proof-of-concept, we have performed similar experiments testing the importance of 
DENV4 genotypic variation (Figure 4.5). The DENV4 serotype is comprised of five genotypes; I, 
IIa, IIb, III, IV (sylvatic), and V (Figure 4.5A). We have generated an isogenic panel of DENV4 
viruses containing the envelope glycoprotein of each genotype and used them in neutralization 
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assays. We find that there is a large range of neutralization against a panel of primary DENV4 
natural infection sera (Figure 4.5B). These results reveal that even following natural infection, 
while there is large breadth of neutralization against all genotypes, some viruses are 
consistently neutralized either better or worse. By applying these same techniques to DENV2 
and Dengvaxia vaccine sera, we will be able to measure any genotype-specific differences in 
the antibody response to vaccination. 
 
4.3 Conclusions 
Early analyses of CYD-TDV suggested it should be successful in large clinical trials 
because in human trials it elicited antibodies that were strongly neutralizing to all four serotypes 
(68). As our understanding of the complex adaptive immune response to DENV infection 
evolves, the metrics used to evaluate vaccine responses has evolved as well. At one point, 
merely the presence of DENV neutralizing antibodies, as determined through binding or cell 
culture based assays (a common correlate for many other vaccines, such as hepatitis B, 
rotavirus and tetanus), was thought to be sufficient as a correlate of protection against DENV. 
We now know the quality of neutralizing antibodies, either serotype-specific or cross-reactive, 
and perhaps epitope specificity of the response, is important in protective immunity. Additionally, 
the epitopes targeted by strongly neutralizing antibodies can be a determinant for their ability to 
be neutralizing or enhancing following natural infection. Given the evolving metric of antibody-
based correlates of protection for DENV, new experiments and analyses of Dengvaxia vaccine 
sera are anticipated to predict the success and failure of the vaccine in different populations. 
Importantly, these new experiments and analyses can be applied to other vaccine platforms as 
well (both Takeda and NIH currently have DENV vaccines in phase III clinical trials) to 
potentially better predict vaccine efficacy (67). Additionally, results of Dengvaxia’s phase III 
clinical trials have reveal the importance of basic research to fully define the adaptive immune 
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response to natural DENV infection, before fully defining metrics of protection, which are critical 
in evaluating vaccine responses.  
 
4.4 Methods 
Depletion assays to remove cross-reactive antibodies 
Polyclonal immune sera were depleted of cross-reactive antibodies as previously 
described (27). Briefly, polystyrene beads were coated with either BSA or purified DENV4 
antigen. Polyclonal immune sera were incubated with bead:antigen complexes at 37°C for 45 
minutes, and repeated two additional times with new bead:antigen mix. Confirmation of 
complete depletion of antibodies was performed using an ELISA. 
 
Focus reduction neutralization assay (FRNT) 
Neutralization assays were performed as previously described (21, 126). Briefly, 
polyclonal immune sera were diluted 4-fold and mixed with virus, Ab:virus complex was 
incubated at 37°C for one hour, then added to confluent Vero cells. After one hour, overlay was 
added and cells were incubated for 4-5 days, then fixed and immunostained as previously 
described (21, 126). 
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Figure 4.1. DENV2 polyclonal immune sera contains high levels of serotype-specific 
antibodies. A) Focus reduction neutralization test was performed using DENV2 (blue) and 
DENV4 (green) viruses with either BSA-depleted (solid line) or DV4-depleted (dashed line) sera 
from a DENV2 immune individual. B) Neut50 (serum dilution factor required to neutralization 
50% of virus) values are extrapolated from full neutralization curves, and percent of 
neutralization from serotype-specific antibodies is measured. 
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Figure 4.2 Dengvaxia immune sera contains varying amount of DENV2 serotype-specific 
antibodies. Dengvaxia immune sera were either control depleted or depleted of cross-reactive 
antibodies (DENV4-depleted) and depleted sera was using in neutralization assays against 
DENV2 and DENV4, and the Neut50 (serum dilution factor required to neutralization 50% of 
virus) values were calculated. Percent of serotype-specific neutralization was calculated from 
Neut50 values. 
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Figure 4.3 DENV2 neutralization titer does not correlate with percentage of serotype-
specific antibodies. DENV2 neutralization titers (serum dilution factor required to neutralization 
50% of virus) were plotted against the percentage of neutralization due to serotype-specific 
antibodies.  
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Figure 4.4 Dengvaxia-elicited DENV2 serotype-specific antibodies target an EDIII epitope. 
DENV2 serotype-specific sera (depleted of cross-reactive antibodies) were evaluated for their 
ability to neutralize DENV2, DENV4, and rDENV4/2, a chimeric DENV4 virus that contains EDIII 
from DENV2. Neut50 values are calculated as the serum dilution factor required to neutralization 
50% of virus. 
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Figure 4.5 DENV genotypic variation can impact polyclonal neutralization. A) The DENV4 
serotype is composed of five genetically distinct genotypes, with genotype II further divided into 
IIa and IIb. A phylogenetic tree was generated using envelope protein amino acid sequences 
using the neighbor-joining method. B) rDENVs containing the envelope protein of each 
genotype were tested for their ability to be neutralized by a panel of DENV4 primary immune 
sera. Neut50 values are calculated as the serum dilution factor required to neutralization 50% of 
virus. 
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CHAPTER 5 – Epitope addition and ablation via manipulation  
of a DENV1 infectious clone4 
 
5.1 Summary 
Despite the clinical relevance, dengue virus (DENV) research has been hampered by 
the absence of robust reverse genetic systems to manipulate the viral serotypes for propagation 
and generation of mutant viruses. In this manuscript, we describe application of an infectious 
clone system for DENV serotype 1 (rDENV1ic). Similar to previous clones in both flaviviruses 
and coronaviruses, the approach constructs a panel of contiguous cDNAs that span the DENV 
genome and can be systematically and directionally assembled to produce viable, full-length 
viruses. Comparison of the infectious clone derived virus with the original isolate reveals 
identical sequence, comparable end-point titers, and similar foci staining. Both focus forming 
assays and percent infection by flow cytometry revealed overlapping replication levels in two 
different cell types. Moreover, serotype-specific monoclonal antibodies (MAbs) bound similarly 
to infectious clone and the natural isolate. Using the clone, we were able to insert a DENV4 
type-specific epitope recognized by primate MAb 5H2 into envelope (E) protein domain I (EDI) 
of DENV1 and recover a viable chimeric recombinant virus. The recombinant DENV1 virus was 
recognized and neutralized by the DENV4 type-specific 5H2 MAb. The introduction of the 5H2 
epitope ablated two epitopes on DENV1 EDI recognized by human MAbs (1F4 and 14C10) that 
strongly neutralize DENV1. Together, the work demonstrates the utility of the infectious clone 
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and provides a resource to rapidly manipulate the DENV1 serotype for generation of 
recombinant and mutant viruses.  
 
5.2 Importance 
Dengue viruses (DENVs) are significant mosquito transmitted pathogens that cause 
widespread infection and can lead to severe infection and complications. Here we further 
characterize a novel and robust DENV serotype 1 (DENV1) infectious clone system that can be 
used to support basic and applied research. We demonstrate how the system can be used to 
probe the antigenic relationships between strains by creating viable recombinant viruses that 
display or lack major antibody epitopes. The DENV1 clone system and recombinant viruses can 
be used to analyze existing vaccine immune responses and inform second-generation bivalent 
vaccine designs. 
 
5.3 Introduction 
Dengue viruses (DENV) represent a significant threat to human health and the global 
economy causing widespread and frequent epidemics (1, 131). Transmitted by female 
mosquitos, the DENV family has four known serotypes that are genetically and antigenically 
related. Infection with any one DENV serotype typically produces asymptomatic or mild disease, 
but induces long-term immunity against that serotype (132). However, subsequent exposure to 
a different serotype may result in more severe disease characterized by dengue hemorrhagic 
fever or dengue shock syndrome often attributed to antibody dependent enhancement (2, 131). 
Overall, potential adverse disease outcomes due to immune cross-reactivity complicates efforts 
to produce effective vaccines against the DENV family (133). 
 
To study aspects of infection and pathogenesis, a number of reverse genetic systems 
have been generated for members of the flavivirus family, which includes DENV (134, 135). 
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These approaches have provided powerful tools to manipulate the viral genome and have given 
insight into viral protein function, virulence determinants, viral immune evasion, host specificity, 
and other virus/host interactions (134). Reverse genetic systems have also facilitated improved 
research methodologies with the development of reporter assays as well as means to produce 
virus like particles and live attenuated vaccines (136, 137). In addition, infectious clones provide 
the opportunity to explore a clonal population of DENV with relatively few mutations versus the 
“mutant spectrum” typically observed in laboratory passaged stocks (138-140). Together, these 
tools have been critical in building a foundation to understanding DENV disease and 
pathogenesis. 
 
Yet, while current systems have been useful, several obstacles remain for DENV 
reverse genetic systems (134). Flavivirus clones are difficult to maintain in bacteria and often 
result in sequence rearrangements or mutations that reduce expression of toxic elements from 
the viral genome. Several approaches have been employed to improve propagation including 
use of low copy plasmid (134), insertion into bacterial or yeast artificial chromosomes (141-143), 
disruption of promoter regions in viral cDNA (144), as well as microbial free propagation 
approaches (145, 146). However, these methods often diminish yields, produce changes in viral 
sequence, or require significant extraneous effort that reduces the overall utility of the 
approaches. Importantly, many of these reverse genetic systems report significant attenuation 
relative to their control wild-type viruses despite similar consensus sequencing (134). Overall, 
these results highlight the obstacles for using reverse genetic systems to study DENV disease 
and pathogenesis. 
 
In this study, we extend our characterization of a dengue virus serotype 1 (DENV1) 
infectious clone (20) by comparing and contrasting the growth and antigenic properties of 
molecularly cloned recombinant and wild-type dengue virus serotype 1 (DENV1). Importantly, 
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DENV1 derived from the clone maintained equivalent replication and complete antibody binding 
fidelity with the wild-type strain. Using the tetrapartite DENV1 molecular clone, we then inserted 
a known DENV4 envelope protein domain I (EDI) neutralization epitope and demonstrated 
efficient gain of neutralization function. However, by introducing these changes, we 
simultaneously ablated two known DENV1 antibody binding sites and disrupted their binding 
and neutralization. Together, the results illustrate the utility of this newly developed infectious 
clone as a platform to study DENV immunity by exchanging functional complex epitopes 
between DENV strains, simultaneously gaining new neutralization properties to other strains 
while ablating the primary neutralizing antigenic sites of DENV1. 
 
5.4 Results 
Design and construction of dengue 1 full-length infectious clone 
The DENV1 infectious clone (rDENV1ic) was synthesized as a panel of four continuous 
cDNA segments that span the entire genome (Figure 5.1A) (20). Based on sequence from a 
laboratory strain of DENV1 West Pac ‘74, each segment is flanked by class IIS restriction 
endonuclease sites that cleave palindromic sequences into asymmetric 3 nucleotide overhangs. 
These overhangs permit directional assembly of the cleaved fragments to generate full-length 
viral cDNA. With the exception of an ablated restriction site (see methods), the sequence 
directly reconstitutes the wild-type laboratory strain. The ligated cDNA fragments are then used 
as a template to produce full-length viral RNA, which is electroporated into C6/36 mosquito 
cells. To demonstrate transfection efficiencies of full-length transcripts, infectious center assay 
indicate low, but stable infection (0.4%) (Figure 5.1B). After several days, cell culture 
supernatant containing progeny rDENV1ic virions is harvested and passaged once on C6/36 
cells to generate working virus stocks.  
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RNA isolated from infected cells was verified relative to the parental wild-type strain 
using genome-length analysis finding no differences in the consensus amino acid sequences. 
Similarly, end-point titers from C6/36 cells (Figure 5.1C) found no notable difference between 
the wild-type and rDENV1ic derived viruses in regards to replication. In C6/36 cells, both wild-
type and infectious clone derived virus maintains similar sized foci following infection (Figure 
5.1D). Together, the results indicate that no replication deficit nor foci formation deficit was 
observed between the wild-type and infectious clone.  
 
Replication kinetics of rDENV1ic 
Some of the previously described reverse genetic systems for DENVs have been 
hampered by replication attenuation relative to the wild-type strain despite identical consensus 
sequences (134). To determine if rDENV1ic is attenuated relative to the wild-type virus, growth 
curves were completed in C6/36 mosquito cells over a seven day time course (Figure 5.1E). 
The data indicates that wild-type and rDENV1ic replicate equivalently, peaking in focus forming 
units 5 days after infection (Figure 5.1E). Percent infection of C6/36 cells also demonstrated no 
significant difference between the wild-type and infectious clone with nearly 100% infection 
observed 4 days after infection (Figure 5.1F). We next examined replication in the human 
monocyte derived U937 cell line stably expressing DC-SIGN, a known DENV attachment factor 
(Figure 5.1G); similar to the C6/36 mosquito cell line, we observed no difference in the 
replication of the wild-type and rDENV1ic in U937+DC-SIGN cells. These results demonstrate 
no detectable attenuation of the rDENV1ic clone relative to the wild-type strain in either insect or 
human cells. 
 
The display of antibody epitopes on rDENV1ic   
Antibody binding and neutralization are a critical issue in DENV pathogenesis in 
humans; as such, the infectious clone and parental WT strain must display the same surface 
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architecture and epitopes. To compare the display of antibody epitopes, ELISAs were 
performed using a panel of DENV1-specific monoclonal antibodies against rDENV1ic and the 
parental wild-type strain (Table 5.1). Monoclonal antibody (MAb) 1F4, derived from a DENV1 
infected patient (27), binds in the envelope domain I (EDI) region and extends into the EDI and 
domain II (EDII) hinge region (84); ELISA with MAb 1F4 produced strong and equivalent binding 
to both the wild-type and infectious clone (Figure 5.2A). Similarly, the EDI, EDIII and EDI/II 
hinge region is the epitope for MAb 14C10, which also bound similarly between the wild-type 
and rDENV1ic (Figure 5.2B). Finally, MAb 1C19.2, an EDIII antibody, also bound similarly to 
both wild-type and rDENV1ic (Figure 5.2C). Together, the results indicate that rDENV1ic 
displays the same antibody epitopes as the wild-type control virus.     
 
We also tested the binding of DENV serotype 2, 3 and 4 monoclonal antibodies (Table 
5.1) to rDENV1ic. Beginning with a DENV2-specific antibody, MAb 2D22 (38), failed to bind to 
either wild-type or rDENV1ic (Figure 5.2D). Similarly, MAb 5J7 (37) also fails to bind to 
rDENV1ic or wild-type strain while efficiently binding DENV3 (Figure 5.2E). Finally, MAb 5H2, 
an EDI antibody specific to DENV4, showed no binding to either DENV1 iteration (Figure 5.2F). 
Together, combined with DENV1 monoclonal data, the results indicate that rDENV1ic has the 
same surface architecture and epitopes as the wild-type strain. 
 
Antibody neutralization of rDENV1ic  
While observing equivalent antibody binding between rDENV1ic and wild-type virus by 
ELISA, neutralization is an even more sensitive functional assay to compare viruses. Small 
changes in binding conformation may induce enhancement versus neutralization; as such, 
these assays must be equivalent between the infectious clone and wild-type to justify the use of 
rDENVic for vaccine and immunogenicity studies. Using a focus reduction neutralization test 
(FRNT), we examined the ability of well-defined MAbs to block virus infectivity. For all three 
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DENV1 monoclonal antibodies (1F4, 14C10, and 1C19.2), percent neutralization was nearly 
identical between the wild-type and rDENV1ic (Figure 5.3A-C). Similar to ELISA results, 
monoclonal antibodies against the other DENV serotypes were unable to neutralize either the 
clone or wild-type virus (Figure 5.3D-F). Extending studies to a U937+DC-SIGN flow-based 
neutralization assay, percent infection results revealed overlapping neutralization of rDENV1ic 
and wild-type following DENV1 monoclonal antibody incubations (Figure 5.4A-C). In addition, 
none of the other DENV serotype specific antibodies provides any significant reduction in viral 
infection (Figure 5.4D-F). Together, the results match the ELISA data and indicate antibody 
neutralization fidelity between the infectious clone and wild-type viruses in two independent 
neutralization assays.     
 
Gain of DENV4 monoclonal binding and neutralization 
To use the rDENVic to study antibody responses to specific epitopes, we generated a 
DENV1 mutant virus that incorporates the DENV4 5H2 epitope into the DENV1 backbone virus. 
5H2 is a DENV4 type-specific and strongly neutralizing MAb isolated from a non-human primate 
infected with DENV4 (80, 147). A high-resolution structure of 5H2 bound to DENV4 E protein 
has led to the identification of 17 residues within EDI that interact with the antibody (Figure 5.5) 
(80, 147). Of these 17 amino acids, five are conserved between DENV1 and DENV4. The 
remaining 12 residues in DENV1 were replaced with those from DENV4, by manipulating 
plasmid A of the DENV1 infectious clone (rDENV1ic-5H2-epitope, herein referred to as 
rDENV1ic-EDI) (Figure 5.6A) (Figure 5.5). The DENV4 MAb 5H2 bound and neutralized the 
rDENV1ic-EDI virus (Figure 5.6B and C). As the parental clone and wild-type DENV1 were not 
recognized by 5H2 (Figure 5.6B and C), these results confirm successful transfer of a 
conformational epitope from DENV4 into DENV1. 
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Ablation of DENV1 monoclonal binding and neutralization 
The epitope of DENV4 MAb 5H2 overlaps with the known DENV1 type-specific epitopes 
recognized by human neutralizing MAbs 1F4 and 14C10 (84). Importantly, 1F4 has over one 
third of its predicted contact residues replaced in the rDENV1ic-EDI virus (Figure 5.7A and 5.5). 
Insertion of the DENV4 5H2 epitope partially disrupted the DENV1 1F4 epitope resulting in a 80-
fold reduction in EC50, but not complete ablation in binding of 1F4 to rDENV1ic-EDI (Figure 
5.7B). Similarly, neutralization assays indicate that 1F4 nearly lost all of its ability to neutralize 
the rDENV1ic-EDI mutant (Figure 5.7C). MAb 14C10 has a smaller percentage (15%) of its 
epitope disrupted in the rDENV1ic-EDI virus (Figure 5.7D and 5.5), as it has additional contact 
residues in EDIII from the neighboring dimer, that are maintained (Figure 5.8) (36). Despite this 
smaller percentage, binding of 14C10 is still reduced (Figure 5.7E) and 14C10 neutralization of 
rDENV1ic-EDI is mostly lost (Figure 5.7F). In contrast, DENV1 monoclonal antibody E103, 
which targets an EDIII epitope (Figure 5.7G) (148), had no significant reduction in ELISA 
binding relative to wild-type or the infectious clone (Figure 5.7H). Additionally, MAb E103 
maintained robust neutralization indicating maintenance of other DENV1 epitopes within the 
mutant virus (Figure 5.7I). In summary the introduction of the 5H2 epitope residues to create the 
rDENV1ic-EDI virus leads to efficient display of a heterologous DENV4 epitope and the 
disruption of two native DENV1 type-specific epitopes. Our results illustrate the utility of the 
infectious clone for transferring DENV epitopes between serotypes, and identifies functional 
consequences on other conserved epitopes within the transferred amino acid regions. 
 
5.6 Discussion 
While a number of reverse genetic systems for dengue viruses have been developed, 
significant obstacles including replication attenuation, sequence alteration, as well as labor and 
cost intensive techniques have limited their utility (134). In this manuscript, we further 
characterize a novel DENV1 molecular clone platform that is patterned after coronavirus 
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systems and describe additional details including transcript infectivity and recombinant virus 
phenotypes in vitro (20, 85, 86, 149, 150). Generating a panel of contiguous cDNAs that span 
the entire genome, the divided DENV1 reverse genetic system overcomes toxic elements within 
itself and allows propagation in bacteria. Importantly, directional assembly and in vitro 
transcription allows electroporation of full length infectious RNA that directly corresponds to the 
wild-type virus sequence. As a result, the infectious clone derived virus maintains similar 
replication in multiple cell types (Figure 5.1E-G) as well as complete fidelity in regard to antibody 
binding and virus neutralization (Figure 5.2 and 5.3). Building on previous epitope swap mutants 
(20, 21), we employed this reverse genetic system to generate a DENV1 viral mutant that 
displayed a known monoclonal antibody epitope from DENV4, gaining 5H2 monoclonal antibody 
binding and neutralization to the donor sequence strain. However, the mutant virus also 
disrupted binding and neutralization of two DENV1 specific monoclonal antibodies despite 
retaining the majority of their targeted antigenic residues (Figure 5.5 and 5.7). While other 
DENV1-specific monoclonal antibodies maintain effective binding and neutralization (Figure 
5.7C), the data highlight the opportunity cost of domain swaps even in the context of partial 
epitope disruption. Overall, the results also illustrate the utility of this newly developed infectious 
clone systems as a platform to study DENV1 infection, pathogenesis and immunity. 
 
For the DENV vaccine field, this reverse genetic system amplifies opportunities in virus 
design that are already being explored. Previous work by our lab has utilized the DENV2 and 
DENV4 infectious clones to define and transfer a critical antibody binding epitope in DENV2 
identified by structural analysis (21, 38). In this case we described a recombinant DENV4 virus 
that displayed a heterologous DENV2 epitope, while preserving the major neutralizing epitopes 
on DENV4 (21). In addition, previous work using this DENV1 infectious clone was able to 
transfer part of the DENV3 MAb 5J7 epitope, resulting in a partial gain of binding and 
neutralization by 5J7, but no loss of binding to DENV1 MAb 1F4 (20). Importantly, both the 
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DENV2 2D22 and DENV3 5J7 MAb epitopes are distinct from the 1F4 and 14C10 epitopes 
transplanted here. Coupled with data from the current manuscript, the approach to disrupt 
epitopes within the context of live virus highlights an independent and powerful approach to 
quickly validate structural predictions of key residues. Importantly, full characterization of these 
viral epitopes and their portability between DENV serotypes opens new approaches to vaccine 
development. Importantly, this work defines a rationally-designed chimeric virus that uses MAb-
envelope structural interactions to identify residues associated with the DENV4 MAb 5H2 
epitope that were sufficient for the gain of binding and neutralization. These changes lead to the 
disruption of multiple overlapping DENV1 epitopes, highlighting a potential problem that must be 
addressed in DENV vaccine design. Interestingly, despite maintaining nearly two thirds of the 
DENV1 1F4 epitope in the chimeric virus, binding and neutralization were almost completely 
lost, indicating that the critical residue determinants for antibody interactions were among those 
that were changed. Another DENV1 MAb, 14C10, which maintained a much larger percentage 
of its epitope in the chimeric virus, lost a smaller amount of binding, yet still lost nearly complete 
neutralization by 14C10. This suggests that while the remaining epitope can still be partially 
bound by 14C10, the interaction is insufficient to fully neutralize the virus. Structure-guided 
design could identify additional residues to further expand the transplanted DENV4 epitope to 
fully ablate DENV1 MAb and polyclonal binding and neutralization. Together, these data 
illustrate the utility of mapping epitopes using a combination of structure and reveres genetics. 
With a similar approach employed for human norovirus (151-155), these resources can be 
applied to generate diagnostic reagents, and to create a map of epitopes ideal for designing 
chimeric bivalent vaccines that produce broad-spectrum neutralization, a critical issue in DENV 
pathogenesis. 
 
Moving beyond vaccine immunity, the infectious clone system provides opportunities to 
contribute to other areas of DENV research. Exploring virus-host interactions has been 
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complicated by attenuation of traditional clone derived virus (134). Our system maintains 
equivalent replication to the wild-type strain, allowing examination of the impact of specific point 
mutations or viral protein deletion without the complication of interpreting baseline clone 
attenuation. In addition to these areas, the infectious clone system may be a useful resource in 
identifying virulence determinants, host specificity, viral protein function, RNA structural 
elements as well as testing of antiviral therapeutics.       
 
Overall, the reverse genetic system characterized in this manuscript represents a major 
resource for the study of DENV1 infection and pathogenesis. Building on previous reports (20), 
this clone system provides several important advantages to study DENV1 including robust 
propagation in bacteria, fidelity to wild-type sequence, and absence of replication attenuation. 
Importantly, both antibody binding and virus neutralization indicate uniform antigenicity with the 
wild-type strain permitting epitope mapping. Coupled with structural studies, the reverse genetic 
system can be manipulated to produce chimeric vaccines harboring conserved epitopes from 
multiple serotypes. While it is unlikely that neutralizing epitopes from all four serotypes could be 
combined into a single viable chimeric DENV virus, it is possible two bivalent viruses could be 
generated that contain neutralizing epitopes from all four serotypes (e.g. rDENV1/3 and 
rDENV4/2). This advance offers a promising strategy to produce broad based protection against 
the DENV family. 
 
5.6 Materials and Methods 
Virus Construction 
Recombinant DENV1 West Pac ’74 infectious clone (rDENV1ic) was constructed using a 
four-cDNA cloning strategy as previously described (20, 21, 87). Briefly, the DENV1 genome 
was divided into four fragments, and subcloned into separate cDNA plasmids with unique type 
IIS restriction endonuclease cleavage sites at the 5’ and 3’ ends of each fragment. A PflMI site 
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was removed using standard molecular techniques. A T7 promoter was introduced into the 5’ 
end of the A fragment, and plasmid DNA was grown in Escherichia coli cells. Purified plasmid 
DNA was enzyme digested, purified, and ligated together with T4 DNA ligase. Infectious 
genome-length capped viral RNA transcripts were generated with T7 polymerase. RNA was 
electroporated into C6/36 cells and incubated 4-6 days. Cell culture supernatant containing virus 
was harvested, centrifuged at maximum speed to remove cellular debris, and passaged onto 
C6/36 cells to generate a passage one virus stock.  
 
rDENV1ic-EDI Mutant Construction 
For mutant virus generation, 12 predicted predicted contact residues of 5H2 (80, 147) 
were identified that differ between DENV1 and DENV4 (Table 1). rDENV1ic plasmid A fragment 
was re-designed to encode these 12 amino acid changes in the envelope protein, to create 
rDENV1ic-EDI. The new A plasmid was digested and ligated with WT rDENV1ic plasmid B, C 
and D, as described above, to generate the rDENV1ic-EDI mutant virus. 
 
Cells   
Cells were cultured as previously described by our group (20, 21). C6/36 cells were 
grown in Gibco minimal essential medium (MEM) at 32°C. DC-SIGN expressing U937 cells 
(U937+DC-SIGN) were maintained in RPMI-1640 at 37°C. Media were supplemented with fetal 
bovine serum (FBS) (5% for C6/36 and U937+DC-SIGN cells) which was lowered to 2% after 
infection. C6/36 and U937+DC-SIGN media were supplemented with nonessential amino acids, 
and U937+DC-SIGN medium were also supplemented with L-glutamine and 2-mercaptoethanol. 
All media were additionally supplemented with 100U/ml penicillin, 100µg/ml streptomycin and 
0.25µg/ml Amphotericin B. All cells were incubated in 5% CO2. 
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Virus Titration and Immunostaining 
24-well cell culture plates were seeded with C6/36 cells to be confluent at time of 
infection. Cell growth media was removed, virus stocks were serially diluted 10-fold then added 
to cells for one hour at 32°C (C6/36) with gentle rocking. After incubation, cells were overlaid 
with 1% methylcellulose in OptiMEM I (Gibco) supplemented with 2% FBS, nonessential amino 
acids and 100U/ml penicillin, 100µg/ml streptomycin and 0.25µg/ml Amphotericin B, and 
incubated at 32°C. After four-six days incubation, overlay was removed, cells were washed with 
phosphate-buffered saline (PBS) and fixed in 80% methanol. Cells were blocked in 5% non-fat 
dried milk in PBS (blocking buffer) then incubated for 1 hour at 37°C with anti-prM MAb 2H2 and 
anti-E MAbs 4G2 and DV1-E103 diluted in blocking buffer. Cells were washed two times with 
PBS, then incubated for 1 hour at 37°C with horseradish peroxidase (HRP)-conjugated goat 
anti-mouse antibody (Sigma) diluted in blocking buffer. Plates were washed two times with PBS, 
and foci were developed using TrueBlue HRP substrate (KPL). 
 
Infectious Center Assay 
C6/36 cells electroporated with rDENV1ic RNA were diluted in OptiMEM I (Gibco), 
added to a confluent monolayer of C6/36 cells, overlaid with 1% methylcellulose and incubated 
for four days. After incubation, cells were fixed and stained as described above. Percent of 
electroporated cells capable of making viable infectious virus was calculated as follows = 
(number foci/number of exlectroporated cells plated) x 100. 
 
Growth Curves 
To determine the amount of virus cells can produce, C6/36 cells were inoculated at a 
multiplicity of infection (MOI) of 0.01. Every 24 hours, all cell culture supernatant was harvested 
(volume was replaced with fresh medium) and frozen at -80°C. Virus samples were titered as 
described above. To determine the kinetics at which cells become infected, C6/36 cells were 
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inoculated at an MOI of 0.01. Every 12 hours, cell culture medium was removed, cells were 
washed with PBS, fixed, permeabilized and probed with anti-prM MAb 2H2 conjugated to 
AlexFluor488. Infected cells were quantified using a Guava flow cytometer (Millipore). 
U937+DC-SIGN cells were infected at an initial infection of 2%, and every 12 hours a sample of 
cells were harvested, fixed and stained as described for C6/36 cells.  
 
Binding Enzyme-Linked Immunosorbent Assay (ELISA) 
Plates were coated with either 100ng/well each mouse MAbs 4G2 and 2H2, or 
200ng/well human MAb 1C19, overnight at 4°C. Plates were washed with Tris-buffered saline 
with 0.05% Tween (TBST) and blocked in 3% non-fat dried milk in TBST (blocking buffer), and 
equal quantities of virus (as previously titrated by ELISA) were added and incubated for 1 hour 
at 37°C. Plates were washed and primary human MAbs were diluted 4-fold in blocking buffer 
and added to plate for 1 hour. Plates were washed and alkaline phosphate (AP)-conjugated 
secondary antibodies were added for 1 hour at 37°C. Plates were washed, developed using p-
nitrophenyl phosphate substrate and color changes were quantified by spectrophotometry as 
previously described (20, 21). 
 
Neutralization Assays 
For the focus reduction neutralization test (FRNT), 24-well cell culture plates were 
seeded with C6/36 cells to be confluent at time of infection. MAbs were diluted 4-fold and mixed 
with ~45 focus-forming units (FFU) of virus, and incubated for 1 hour at 32°C. After incubation, 
virus:MAb mixture was added to C6/36 cells for 1 hour at 32°C with gentle rocking. Overlay was 
added and cells were incubated 4-6 days. Cells were fixed and stained as described above. For 
the flow-based neutralization assay, MAbs were diluted 4-fold and mixed with virus (previously 
titrated to equal ~15% infection with no MAb present), and incubated for 1 hour at 37°C. After 
incubation, virus:MAb mixture was added to 5x104 U937+DC-SIGN cells for 2 hours at 37°C. 
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Cells were then pelleted and washed two times with fresh medium, then incubated for 24 hours. 
After incubation, cells were fixed, permeabilized and stained as described above for U937+DC-
SIGN growth curves. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
104 
 
 
Figure 5.1. DENV1 infectious clone design, characterization and growth. (A) Structure of 
DENV1 viral genome and division into the four subgenomic fragments designated plasmids A 
(nucleotides 1-2052), B (2053-4215), C (4216-8563) and D (8564-10736). (B) Full-length viral 
RNA was electroporated into C6/36 cells, cells were diluted and added to confluent C6/36 cells. 
After incubation, infected cells were stained to determine initial percentage of electroporated 
cells capable of producing infectious virus. (C) Peak infectious titers of virus stocks were 
determined on C6/36 cells. (D) Immunostaining of DENV1 and rDENV1ic foci in C6/36 cells. (E) 
C6/36 cells were inoculated at an MOI of 0.01 and every 24 hours, supernatant containing virus 
was harvested and subsequently titered on C6/36 cells. (F) C6/36 cells were inoculated at an 
MOI of 0.01, or (G) 1% of U937+DC-SIGN cells were infected, and every 12 hours, cells were 
harvested, stained for intracellular viral antigen, and total percentage of infected cells was 
calculated. 
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Figure 5.2. rDENV1ic is only bound by DENV1-serotype specific antibodies. DENV1 and 
rDENV1ic were analyzed for their ability to bind (A-C) DENV1-serotype specific antibodies 1F4, 
14C10, and 1C19.2 or (D-F) DENV2, DENV3 and DENV4-serotype specific antibodies, 2D22, 
5J7 and 5H2, respectively, in an ELISA virus capture assay.  
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Figure 5.3. rDENV1ic maintains fidelity to DENV1-serotype specific antibodies in a focus 
reduction neutralization test. Neutralization of DENV1 and rDENV1ic by monoclonal 
antibodies was measured in a C6/36 focus reduction neutralization test (FRNT) using (A-C) 
DENV1-serotype specific MAbs 1F4, 14C10 and 1C19.2 and (D-F) DENV2, DENV3 and 
DENV4-serotype specific antibodies, 2D22, 5J7 and 5H2, respectively. 
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Figure 5.4. rDENV1ic is only neutralized by DENV1-serotype specific antibodies in a flow-
cytometry based neutralization test. Neutralization of DENV1 and rDENV1ic by monoclonal 
antibodies was measured in U937+DC-SIGN flow-cytometry neutralization assay using (A-C) 
DENV1-serotype specific MAbs 1F4, 14C10 and 1C19.2 and (D-F) DENV2, DENV3 and 
DENV4-serotype specific antibodies, 2D22, 5J7 and 5H2, respectively. 
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Figure 5.5 Virus amino acid sequences and MAb epitopes. Amino acid sequences for wild-
type rDENV1ic, rDENV4ic are shown with chimeric rDENV1ic-EDI residues highlighted in 
orange (DENV4 amino acid transplanted into DENV1 backbone sequence). rDENV1ic-EDI virus 
that was recovered contained an additional mutation (light orange) unrelated to the transplanted 
5H2 epitope. Contact residues for MAbs 5H2, 1F4, 14C10 and E103 are shown in green, 
magenta, purple and cyan, respectively. 
 
 
 
Residue 
Domain I and II   Domain III 
46
 
47
 
49
 
51
 
52
 
13
1 
13
2 
13
5 
13
6 
13
8 
15
5 
15
6 
15
7 
15
9 
16
0 
16
1 
16
2 
16
3 
16
5 
16
6 
16
7 
16
8 
17
0 
17
1 
17
2 
17
3 
17
4 
17
5 
17
6 
17
7 
17
9 
18
0 
27
3 
27
4 
27
5 
27
6 
29
1 
29
3   29
9 
30
3 
30
7 
30
8 
31
0 
32
8 
32
9 
33
0 
33
2 
33
4 
38
4 
38
5 
39
0 
rDENV1ic L K E T N Q Y L K S T T E G T I A T T P Q A T S E I Q L T D G A S G T T K T  Y T K L K G T D P K E K S 
rDENV1ic-EDI L K E T N Q Y L K S A T E G V T A M T P Q S S V E V K L P D G E S G T T K R  Y T K L R G T D P K E K S 
rDENV4ic T K T K E Q I L E T A S N G V T A M T P R S S V E V K L P D G E G D G N K R  Y S S I K G A G P K N S H 
                                                    
5H2 residues                                                     
1F4 residues                                                     
14C10 residues                                                     
E103 residues                                                     
  
 
109 
 
 
Figure 5.6. rDENV1ic-EDI gains binding and neutralization to DENV4-serotype specific 
MAb 5H2. (A) Structure of DENV envelope protein dimer showing transplanted residues from 
DENV4 (orange) and MAb 5H2 epitope contact residues (green). Residues that are part of both 
the 5H2 MAb epitope and rDENV1ic-EDI virus are shown as orange. rDENV1ic-EDI virus that 
was recovered contained an additional mutation (light orange) unrelated to the transplanted 5H2 
epitope. (B) Viruses were analyzed in an ELISA virus capture assay for their ability to bind 
DENV4-specific MAb 5H2. (C) Neutralization of viruses in C6/36 focus reduction neutralization 
test (FRNT) with DENV4-specific MAb 5H2. 
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Figure 5.7. rDENV1ic-EDI loses binding and neutralization to EDI DENV1-serotype 
specific MAbs. Structure of DENV envelope protein dimer showing transplanted residues from 
DENV4 (orange) and MAb epitope contact residues for (A) 1F4 (magenta), (D) 14C10 (purple) 
and (G) E103 (cyan). Residues that are part of both the MAb epitope and rDENV1ic-EDI virus 
are shown as orange. rDENV1ic-EDI virus that was recovered contained an additional mutation 
(light orange) unrelated to the transplanted 5H2 epitope. Viruses were analyzed in an ELISA 
virus capture assay for their ability to bind MAbs (B) 1F4, (E) 14C10 and (H) E103. 
Neutralization of viruses in C6/36 focus reduction neutralization test (FRNT) with MAbs (C) 1F4, 
(F) 14C10 and (I) E103. 
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Figure 5.8. 14C10 epitope spans into EDIII from neighboring dimer. The 14C10 epitope sits 
primarily over EDI of a single envelope dimer, but it interacts with additional residues of EDIII in 
the adjacent envelope dimer. 
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Serotype-Specificity MAb Species Epitope 
DENV1 
1F4 Human EDI, EDI/II hinge 
14C10 Human EDI, EDI/II hinge 
1C19.2 Human EDIII 
E103 Mouse EDIII 
DENV2 2D22 Human EDIII/EDII 
DENV3 5J7 Human EDI/II hinge 
DENV4 5H2 Human EDI 
 
Table 5.1. Monoclonal antibody serotype-specificity and epitopes. Serotype-specificity, 
species and epitopes of MAbs used in experiments 
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CHAPTER 6 – Discussion 
 
6.1 Overview of Human Antibody Response to Dengue Infection 
The last ten years has seen a shift in the field’s understanding of human DENV 
antibodies (66, 67). Decades of prior research using anti-DENV mouse monoclonal antibodies 
was critical to our basic understanding of DENV-MAb interactions and virus biology, but 
importantly, did not completely inform our understanding of the human antibody response. While 
mice generate neutralizing antibodies to an immunodominant, simple EDIII epitope, humans 
target different regions encompassing more complex epitope structures that span monomers or 
are dependent on particle morphology (64). This shift has not only placed a new emphasis on 
the importance of studying human monoclonal and polyclonal antibodies to better understand 
the human adaptive immune response to DENV infection, but also provides new leads for the 
development of therapeutics. Importantly, with our growing knowledge on this subject, our 
metrics of antibody-based protection have changed greatly. My PhD research substantially 
contributes to our current understanding of the human antibody response to DENV infection and 
vaccination. Specifically, I defined major antigenic sites on DENV2 targeted by strongly 
neutralizing antibodies produced by memory B cells and long-lived plasma cells in people 
exposed to natural infections or vaccines. While polyclonal serum antibody responses to DENVs 
are known to be a complex mixture of different specificities, my studies indicate that the 
functionally neutralizing response was relatively simple and directed to one or two 
immunodominant sites. My work has been used to evaluate vaccine responses to DENV 
infection, and better inform the design of next-generation vaccines (22, 156-158).  
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For many viruses, the mere presence of virus-specific antibodies is a strong correlate of 
protection, and thus, many vaccines have been developed and evaluated by their ability to elicit 
high titers of antibodies. Following a natural DENV infection, individuals generate large 
populations of specific IgG antibodies (64). These antibodies are comprised of a population of 
serotype-specific neutralizing antibodies that are specific to the infecting serotype, but 
importantly, there is also a population of cross-reactive non-neutralizing antibodies (12). 
Therefore, despite being immune to only the infecting serotype, and susceptible to reinfection 
with any of the three remaining serotypes, individuals would test positive for the presence of 
antibodies reactive to all four serotypes (12). This highlights the difference between DENV and 
many other human virus pathogens, reveals the complexity of the adaptive immune response to 
flaviviruses, and complicates the use of the presence of anti-DENV antibodies as a correlate for 
protection.  
 
6.2 My Contributions to the DENV Antibody Field 
To better understand the properties of human antibodies that protect people from DENV 
infections, I studied both the quantity and quality of neutralizing antibodies in DENV-naïve 
individuals that were naturally infected with DENV (primary infections) or vaccinated with 
monovalent or tetravalent DENV vaccines. In my research I used antibody depletion methods 
and developed novel recombinant DENVs to characterize the molecular specificity and 
functional properties of different antibody populations in human immune sera. While previous 
studies with human DENV-immune sera mainly focused on measuring absolute levels of 
neutralizing antibodies, my results reveal new layers of information about the molecular 
properties the human antibody response to DENV infection. Recent studies indicate that the 
mere presence of DENV neutralizing antibodies is not sufficient for protection (68, 69). I propose 
that metrics that consider both the molecular specificity and level of neutralizing antibodies are 
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likely to be better correlates of protection than current metrics based on the presence or level of 
neutralizing antibody. 
 
Basic research on the properties of human DENV monoclonal antibodies has identified 
critical epitopes for each serotype targeted by both monoclonal and polyclonal antibodies (20, 
23, 27, 35, 37, 38, 87, 103, 126, 159). My research has focused on describing the properties of 
human DENV1 and DENV2 monoclonal and polyclonal antibodies, and the epitopes they target 
on the DENV envelope protein (103, 126, 159). My work with DENV1 has shown that multiple 
strongly neutralizing human antibodies target a complex EDI epitope (103). Importantly, while 
the epitopes of these antibodies are overlapping, the specific residues on the envelope that the 
antibody interacts with vary. This reveals that there is not a single epitope, but instead of 
broader region that likely contains and encompasses the epitopes of many monoclonal and 
polyclonal antibodies. Additionally, I have shown that there is plasticity within the envelope 
protein, and that these neutralizing epitopes can be transplanted between serotypes, while 
maintaining their functionality (103).  
 
My research studying immunity to DENV2 infection has revealed that there are two 
dominant neutralizing quaternary epitopes (126, 159). I found that the epitopes defined by 
monoclonal antibodies from two individuals, are representative of polyclonal antibody 
neutralizing epitopes across a range of different individuals exposed to natural infections or live 
attenuated vaccines, however the specific levels of these antibodies vary among individuals. 
Like DENV1, these epitopes are transferrable between serotypes, resulting in chimeric viruses 
that contain these functional, neutralizable epitopes. My work defining individual antibodies 
epitopes, generating recombinant viruses that capture those epitopes, and using these viruses 
as tools to map polyclonal antibody epitopes has advanced our ability to dissect the properties 
of the complex human antibody response to DENV infection and vaccination.  
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These types of experiments add yet another parameter to evaluate antibody-based 
correlates of protection, by determining the epitopes targeted by serotype-specific antibodies 
(67). Currently, the best correlate of protection against DENV infection is the presence of high 
levels of neutralizing antibodies (66, 67). However within this broad metric, we know very little 
about the properties of these antibodies that are necessary to provide protection, such as their 
absolute level, the amount that are serotype-specific, or the epitopes that they target. Whether 
anti-DENV antibodies protect by providing sterilizing immunity upon subsequent infection, or 
through another mechanism is unknown. Using techniques, tools, and results generated from 
my thesis research, the field can begin to answer these questions.  
 
6.3 Implications of DENV Antibody Immunity, Vaccines and Enhanced Disease 
In addition to strongly neutralizing antibodies, people exposed to primary infections 
generate serotype cross-reactive antibodies, which are poorly neutralizing and not correlated 
with durable protective immunity (12). These antibodies have been implicated in enhancing 
disease during secondary infections via a theory known as antibody dependent enhancement 
(ADE) (13). The ADE theory postulates that cross-reactive and poorly neutralizing antibodies 
enhance infection by forming Ab:virus immune complexes that are infectious to some Fc-
receptor bearing human cells. The concentration of cross-reactive antibody required for ADE to 
occur in people is unknown, but it is thought that it is most likely to occur when these antibody 
levels are relatively low (13). Indeed, recent analyses have revealed that during naturally 
acquired DENV infections, high levels of antibodies protect against severe disease, but ADE 
only occurs at a low, narrow range of pre-existing anti-DENV antibody titers (89). As human 
polyclonal DENV antibodies are important in not only protection, but also enhanced disease, it is 
critical that we fully define their properties to better understand natural infection, but also to 
evaluate DENV vaccines. 
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An effective DENV vaccine should result in an independent, robust antibody response to 
all four serotypes simultaneously (3, 71, 73, 97, 160). If the immune response is unbalanced, it 
can result in populations of antibodies that enhance a natural infection via the mechanism of 
antibody dependent enhancement (ADE) (13). Indeed, this unfortunately appears to be the case 
with Sanofi Pasteur’s live attenuated tetravalent DENV vaccine, Dengvaxia (68, 121, 122). 
Since non/poorly-neutralizing cross-reactive antibodies are implicated in causing enhanced 
disease via ADE, it is critical that an effective vaccine either does not elicit this population of 
antibodies, or is able to generate large populations of strongly neutralizing antibodies to provide 
enough sterilizing immunity so that enhancement cannot occur. Using depletion techniques and 
other assays, and recombinant viruses that I have developed and characterized, we can 
distinguish between these different types of enhancing and neutralizing antibodies, and evaluate 
the likelihood of enhanced disease following vaccination. 
 
6.4 Overview of Progress and Pitfalls of DENV Vaccines 
As our understanding of antibody-based immunity to DENV infection has evolved, the 
metrics used to evaluate vaccines has changed as well. Using the MAbs, recombinant viruses 
and reagents that I have generated, we have evaluated the antibody response to multiple DENV 
vaccine platforms to compare vaccine-elicited antibody-based responses with those from 
natural DENV infections. Early pre-clinical and clinical results from Dengvaxia trials, revealed 
that the vaccine elicited high levels of neutralizing antibodies that neutralized all DENV 
serotypes, suggesting individuals would be protected (68). Breakthrough infections in individuals 
with high levels of neutralizing antibodies revealed that the mere presence of these antibodies is 
not an accurate correlate of protection (68, 69). More recent evaluation of the quality of 
response following vaccination has revealed that although there is cross-neutralization of all 
serotypes, this is not primarily due to serotype-specific antibodies, which are known to be critical 
for protection (22). Rather, the vaccine elicits cross-reactive neutralizing responses suggesting 
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that qualitative differences in adaptive immune targeting can affect vaccine performance. Using 
results I’ve discussed, through studying DENV antibodies following natural infection, we can 
continue to improve design of next-generation DENV vaccines and more accurately evaluate 
them (66, 67).  
 
6.5 Comparison to Other Viruses 
My PhD work has defined multiple human DENV monoclonal antibodies and the 
quaternary epitopes that they target (103, 126, 159). The assays and techniques used to 
identify the properties of anti-DENV antibodies are applicable to many other viruses as well 
(161). With the emergence of Zika virus (ZIKV) in 2015, while some groups focused on 
generating mouse antibodies, other groups were able to rapidly isolate and generate strongly 
neutralizing human antibodies (29-31). This was aided using assay developed and optimized in 
the DENV field, especially the use of techniques that allow for detection of antibodies 
recognizing quaternary epitopes (29-31). Indeed, like DENV and West Nile Virus (WNV) (27, 
32), the potently neutralizing antibodies responsible for human polyclonal neutralization of ZIKV, 
target many of the same quaternary epitopes as previously identified for these other flaviviruses. 
Decades of research on DENV antibodies enabled the field to quickly identify these critical 
antibodies, and harness them for diagnostic, vaccine and therapeutic applications (161, 162). 
 
Quaternary epitopes targeted by human neutralizing antibodies is not limited to the 
flavivirus field. More recently it has been found that many human neutralizing antibodies against 
both Marburg and Ebola viruses target quaternary epitopes on the virus glycoproteins (163, 
164). These epitopes span across monomers within the trimeric glycoprotein, and have been 
suggested to neutralize virus by either blocking receptor interactions or locking proteins and 
preventing conformational changes required for infection (163, 164). These exact mechanisms 
have been shown with DENV quaternary epitope antibodies (160, 161), suggesting these are 
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potentially conserved mechanisms across diverse virus families. Indeed, human antibodies 
targeting quaternary epitopes have been identified for HIV, influenza, norovirus and likely will be 
identified for many other viruses as well (165-168). 
 
6.6 Future Directions for the Flavivirus Field 
Results presented in this dissertation have contributed to expanding our understanding 
of the human antibody response to both natural DENV infection and vaccination. Additionally, 
simultaneous work defining other aspects of DENV immunity, including innate immune 
responses (169), T-cell components (96), and viral determinants of severe disease (170), has 
further refined our understanding of the complete immune response to human DENV infection. 
 
Despite these advances made in DENV immunology research over the last decade, the 
failure of Sanofi Pasteur’s Dengvaxia vaccine, has presented a challenge to our field. Unlike 
many viral pathogens, development of a successful DENV vaccine has been complicated by the 
risk of incomplete protection leading to more severe disease due to ADE (3, 72, 73). Given 
these concerns, DENV vaccine progress has been especially slow, with extensive pre-clinical 
and clinical testing (73). Despite this decades-long process of vaccine development, many of 
the issues seen with Dengvaxia were unexpected considering what was known at the time, and 
have highlighted critical gaps in understanding DENV immunity. Specifically, we still do not 
know the locations of all neutralizing epitopes for each serotype, or for cross-neutralizing 
antibodies that are generated after secondary infections. Additionally, it is unclear what epitopes 
enhancing antibodies target, and if these vary between the four DENV serotypes. As we further 
define these antibodies and their epitopes, we will be closer to generating antibody-based 
correlates of protection, which will be critical in evaluating DENV vaccines. In addition to anti-E 
antibodies, the role of antibodies directed at the NS1 protein, along with T-cell immunity is not 
fully known, but is likely also part of a protective immune response to DENV infection. 
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Knowing what we know now from my studies and the work of others, the failure of 
Dengvaxia in naïve individuals was predictable. While vaccination elicited high levels of 
neutralizing antibodies to all four serotypes, it is now clear that the quality of the antibodies 
might not have been protective, but instead, enhancing (4, 22, 68, 121). The new insights and 
tools generated from my work can be used in preclinical studies to evaluate vaccine efficacy in 
naïve populations, beyond the mere presence of neutralizing Abs. There were other surprises 
from the phase III clinical trials that we did not expect however, such as the drastic differences 
in vaccine efficacy against different genotypes within a single serotype, namely for DENV4 
(130). This highlights the fact that, despite the rapid advances the field has collectively made, 
there are aspects of DENV immunology that we haven’t yet begun to understand. My recent 
work has looked at the role of genotypic variation within DENV4. We find that in evaluating 
vaccine responses, it is critical to study multiple genotypes, especially those currently circulating 
in human populations and causing disease, to fully capture the vaccine-elicited antibody 
response. 
 
Sustained fundamental research of both the virus and the host will continue to elucidate 
the complex relationship between DENV and the hosts it infects. In addition, research 
understanding other aspects of DENV, including its vector, epidemiology, clinical 
manifestations, and reservoir hosts, will further fill in our existing knowledge gaps.  
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APPENDIX 
 
In addition to the work discussed in this dissertation, I have contributed to other 
published and unpublished projects, detailed below. These have been in collaboration with 
talented scientists both at UNC and other institutions.  
 
In collaboration with Kenneth Dinnon III, we performed and published a study investigating 
the role of the Zika virus envelope protein’s contribution to virus stability.  
Gallichotte EN, Dinnon KH III, Lim XN, Ng TS, Lim EXY, Menachery VD, Lok SM, Baric RS. 
“CD-loop extension in Zika virus envelope protein key for stability and pathogenesis”. J 
Infect Dis. 2017 Dec 5;216(10):1196-1204 
 
 
As briefly discussed in chapter 4, I have completed a project investigating the role of 
genotypic variation within DENV serotype 4, on many aspects of virus biology, and virus 
antibody interactions.  
Gallichotte EN, Baric TJ, Nivarthi U, Graham R, Widman DG, Yount BL, Durbin A, 
Whitehead S, de Silva AM, Baric RS. “Genetic variation between dengue virus type 4 strains 
impacts human antibody binding and neutralization”. Under review 
 
 
I assisted with the development and characterization of Zika virus infectious clones, 
resulting in the two following publications. 
Widman DG, Young E, Yount BL, Plante KS, Gallichotte EN, Carbaugh DL, Peck KM, 
Plante J, Swanstrom J, Heise MT, Lazear HM, Baric RS. “A Reverse Genetics Platform That 
Spans the Zika Virus Family Tree”. MBio. 2017 Mar 7;8(2) 
 
Swanstrom JA, Plante JA, Plante KS, Young EF, McGowan E, Gallichotte EN, Widman 
DG, Heise MT, de Silva AM, Baric RS. “Dengue Virus Envelope Dimer Epitope Monoclonal 
Antibodies Isolated from Dengue Patients are Protective Against Zika Virus”. MBio. 2016 Jul 
19;7(4) 
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I contributed to experimental design, data generation, data analysis, and writing and editing 
for the four following papers. 
Nivarthi UK, Kose N, Sapparapu G, Widman D, Gallichotte E, Pfaff JM, Doranz BJ, 
Weiskopf D, Sette A, Durbin AP, Whitehead SS, Baric R, Crowe JE Jr, de Silva AM. 
“Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to 
DENV4 Infection and Vaccination”. J Virol. 2017 Feb 14;91(5) 
 
Liu P, Ridilla M, Patel P, Betts L, Gallichotte E, Shahidi L, Thompson NL, Jacobson K. 
“Beyond attachment: roles of DC-SIGN in dengue virus infection”. Traffic. 2017 
Apr;18(4):218-231 
 
Metz SW, Gallichotte EN, Brackbill A, Premkumar L, Miley MJ, Baric R, de Silva AM. “In 
Vitro Assembly and Stabilization of Dengue and Zika Virus Envelope Protein Homo-Dimers”. 
Sci Rep. 2017 Jul 3;7(1):4524 
 
Swanstrom J, Henein S, Plante J, Yount B, Widman D, Gallichotte EN, Dean H, Osorio JE, 
Parditos CD, de Silva AM, Baric RS. “Analyzing the human serum antibody responses to a 
live attenuated tetravalent dengue vaccine (TDV) candidate”. J Infect Dis. In press 
 
 
All copyrighted material included in this dissertation is used with permission from the 
relevant copyright holders. 
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